Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals by Gollnest, Tristan et al.
ARTICLE
Received 10 Jul 2015 | Accepted 23 Sep 2015 | Published 27 Oct 2015
Lipophilic prodrugs of nucleoside triphosphates as
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The antiviral activity of nucleoside reverse transcriptase inhibitors is often limited by
ineffective phosphorylation. We report on a nucleoside triphosphate (NTP) prodrug approach
in which the c-phosphate of NTPs is bioreversibly modified. A series of TriPPPro-compounds
bearing two lipophilic masking units at the c-phosphate and d4Tas a nucleoside analogue are
synthesized. Successful delivery of d4TTP is demonstrated in human CD4þ T-lymphocyte
cell extracts by an enzyme-triggered mechanism with high selectivity. In antiviral assays, the
compounds are potent inhibitors of HIV-1 and HIV-2 in CD4þ T-cell (CEM) cultures. Highly
lipophilic acyl residues lead to higher membrane permeability that results in intracellular
delivery of phosphorylated metabolites in thymidine kinase-deficient CEM/TK cells with
higher antiviral activity than the parent nucleoside.
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O
ver the last decades, a variety of nucleoside analogues
were applied in antitumour and antiviral therapy and still
play an important role to combat HIV, herpes virus,
hepatitis B and hepatitis C virus infections1,2. The target of these
nucleoside analogue drugs is the inhibition of the virus-encoded
DNA polymerases, such as the HIV reverse transcriptase (RT)3,4
or the HCV-encoded RNA-dependent RNA-polymerase NS5B
(ref. 5), which are the key enzymes in the replication cycle of HIV
and HCV, respectively. To date, eight nucleoside analogues have
been approved as HIV RT inhibitors (NRTIs)6. NRTIs are still
used as the backbone of the combined antiretroviral therapy7.
However, the antiviral efficacy of nucleoside analogues, such
as the thymidine analogue 30-deoxy-20,30-didehydrothymidine 1
(d4T) and 30-deoxy-30-azidothymidine (AZT), is dependent on
the activity of host cell kinases metabolizing these nucleoside
analogues into their antivirally active triphosphate forms
(nucleoside triphosphates, NTPs)8–11.
The stepwise transformation via the nucleoside mono- (NMP)
and diphosphates (NDP) into the corresponding NTP often
occurs insufficiently because of the high substrate specificity of
the involved kinases (Supplementary Fig. 1). Furthermore, many
nucleoside analogues have limitations such as poor biological
half-lives, variable bioavailability after oral administration or
selection of drug resistance, which reduce their clinical
efficacy12,13. To overcome these hurdles, the usage of prodrugs
of the phosphorylated metabolites have been explored in the
past14,15.
In the case of d4T 1, the first phosphorylation step to yield its
monophosphate form 2 catalysed by the host cell enzyme
thymidine kinase (TK) is metabolism-limiting because of the
rather modest affinity of d4T 1 to TK as an alternative substrate
and because TK activity is S-phase-dependent11,16,17. However, to
avoid this limitation, it is not possible to apply the charged
monophosphorylated metabolite because of the high polarity and
thereby extremely poor, if any, membrane permeability. The
development of nucleotide prodrugs capable of delivering
the monophosphorylated metabolite and thereby bypassing the
intracellular activation offered advantages over the use of
the corresponding nucleoside analogue18,19. Moreover, lipophilic-
masked NMPs such as 3 are less vulnerable to degradation by
unspecific phosphatases present in the blood. This enhanced not
only the plasma half-life but also enables the prodrug to be taken
up by cells through passive diffusion20,21. A number of successful
NMP prodrug strategies were reported in the past that efficiently
bypass the nucleoside kinase hurdle. These prodrug forms such as
phosphoramidates and cycloSal-phosphate triesters of nucleoside
analogues were indeed shown to deliver the NMP either by
chemical or enzymatic hydrolysis in the target cells22–27. In
addition to NMPs also the successful delivery of acyclic nucleoside
phosphonates such as cidofovir has been reported28. However, all
these approaches delivered the monophosphor(n)ylated forms of
the nucleosides that subsequently needed further phosphorylation
into the triphosphate forms by cellular kinases to inhibit their target
polymerase.
However, not in all cases such NMP prodrug strategies were
successful. For instance, in the case of AZT the metabolism is
limited by the second conversion step, the formation of
AZT-diphosphate by thymidylate kinase10,29. In this case, a
lipophilic prodrug that intracellularly releases the NDP would be
desirable. At the same time, this would avoid toxicity caused by
the parent nucleoside or the accumulation of the monophosphate
form30. A further example is 20,30-dideoxy-20,30-didehydrouridine
(d4U). The parent nucleoside proved to be completely inactive
against HIV replication in cell cultures. In contrast, the
triphosphate form of d4U is one of the most effective inhibitors
of the HIV’s RT31.
We reported on NDP prodrugs (DiPPro-approach), which
selectively released NDPs not only in phosphate buffer (pH 7.3)
but for the first time also in CEM cell extracts32–35. These
compounds showed very good antiviral activity in TK-deficient
CEM/TK cell cultures infected with HIV, proving the uptake of
the compounds and the delivery of at least phosphorylated
metabolites, most likely the NDP. The uptake of those
compounds was achieved by two acceptor-substituted
benzylesters linked to the b-phosphate group of the NDP. The
stability of the compounds correlated with the length of the
aliphatic residue of the mask32,33. However, we have shown that
the delivery of the corresponding mono- or diphosphates from
prodrug forms (such as the cycloSal- or DiPPro-compounds) did
not improve the antiviral activity34. Importantly, in the same
study we have proven that d4U diphosphate was a very poor
substrate for the NDP kinase, the enzyme that is generally
accepted to be involved in the conversion of NDPs into their
triphosphate forms. Thus, this study showed that the
phosphorylation of nucleotide analogues by NDP kinase can be
also rate-limiting in the activation process of a nucleoside
analogue34,36. As a consequence, the development of
nucleoside triphosphate prodrugs would be highly interesting
and desirable because this would bypass all steps of intracellular
phosphorylation and would maximize the intracellular
concentration of the ultimately bioactive NTP. Although this
has been recognized before11, it was also claimed that the
development of prodrugs of NTP is chemically not feasible
because of the low stability of such compounds37. For this reason,
NTPs were very rarely used as drug platforms because of
their expected poor deliverability and their high sensitivity for
enzymatic dephosphorylation. Thus, very few reports on potential
triphosphate prodrugs have been reported38,39. In addition, in the
few reported examples the yields in the chemical synthesis were
poor, and additionally the compounds proved hydrolytically very
unstable. A difficulty that has to be taken into account in the
development of NTP prodrugs is related to the energy-rich
phosphate anhydride bonds within the triphosphate unit. Under
physiological conditions, these linkages are only kinetically stable
because of the charges present at that moiety, which prevent
nucleophilic reactions that end up in the cleavage of these
anhydride bonds but can be enzymatically cleaved. Interestingly,
c-modification of NTPs by esterification or replacement of the
c-phosphate group by a phosphonate moiety led to a marked
increase in enzymatic stability of the triphosphate unit40,41. On
the other hand, complete lipophilic modification and thereby
neutralization of the charges would significantly increase
the reactivity of the triphosphate unit. For completeness, it
should be added that the delivery challenge for NTPs has also
been addressed by formulating these compounds with cationic
nanogels. However, this approach still requires elaboration
with respect to their toxicity, immunogenicity and
pharmacokinetics42,43.
Here we disclose the development of a novel prodrug concept
for NTPs that releases directly NTPs with high selectivity by an
enzyme-triggered mechanism and thus allows the bypass of all
phosphorylation steps normally needed for the activation of a
nucleoside analogue (Supplementary Fig. 2). To achieve this goal,
the g-phosphate group of a NTP was modified by esterification
with acyloxybenzyl moieties (TriPPPro-compounds). By
fine-tuning the lipophilicity through the use of different acyl
esters the chemical stability also proved controllable so that the
polarity caused by the remaining charges at the a- and
b-phosphates could be efficiently compensated.
The cleavage of the prodrug moieties is initiated by an
enzymatic hydrolysis of the phenolic acyl-ester. This reaction
leads to a spontaneous cleavage of the benzyl C–O bond forming
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first a monomasked intermediate of the NTPs. This process is
repeated for the second mask so that finally the NTP is formed32.
Lipophilic aliphatic esters have proven to be suitable for prodrugs
to allow entering the cell independently of nucleoside transporters
but to enable removal of the lipophilic prodrug moieties by
cellular esterases/lipases44. Moreover, fatty-acid esters are known
to be taken up by the mononuclear phagocyte system. These cells
are important in the pathogenesis of AIDS and are considered to
be reservoirs for HIV particles45,46.
We report on the synthesis of NTP prodrugs 3 bearing
two identical 4-alkanoyloxybenzyl- (a–k), 4-alkoxycarbony-
loxybenzyl- (l–n) and 4-aminocarbonyloxybenzyl groups (o–q),
their hydrolysis properties in different media, the hydrolysis
mechanism, primer extension assays and their anti-HIV activity.
In addition, the synthesis of the monomasked (4-alkyloxybenzyl)-
d4TTPs 4a,e,j is reported. As a model nucleoside analogue, d4T 1
was used to allow a comparison of the TriPPPro-compounds 3
with the DiPPro-compounds.
Results
Synthesis of TriPPPro-d4T triphosphate prodrugs 4. For the
synthesis of TriPPPros-d4TTP prodrugs 3 a convergent strategy
using a dicyanoimidazol (DCI)-mediated coupling of an
appropriate phosphoramidite 5 and d4TDP 6 to form the
energetically rich pyrophosphate moiety in the last step was
performed (Fig. 1). First, d4T 1 was prepared in good overall
yields according to a three-step protocol reported by Horwitz47.
From that compound, d4TDP 6 was prepared by applying the
cycloSal technique (55% yield) because it has been reported that
acceptor-substituted cycloSal nucleotides gave access to
diphosphorylated compounds by using tetra-n-butylammonium
phosphate as a nucleophile48. Therefore, the 5-chloro-substituted
cycloSal-phosphate triester 7 was synthesized starting from d4T 1
with 5-chlorosaligenylchlorophosphite 8 followed by oxidation
with tert-butylhydroperoxide to give the product 7 as a mixture of
two diastereomers in high yields.
Despite its very difficult chromatographic properties, the
resulting crude (n-Bu)4Nþ -salt 6 was purified by automatic
RP-18 flash chromatography without additional ion exchange.
The hygroscopic tetra-n-butylammonium salt form of d4TDP 6
was co-evaporated in dimethylformamide (DMF) and dried in
high vacuum before the coupling reaction to ensure dry reaction
conditions. The use of tetra-n-butylammonium counterions
afforded a higher reactivity and better solubility in organic
solvents. D4TDP 6 was then reacted with a series of phosphor-
amidites 5 in a very fast DCI-mediated coupling reaction and was
oxidized32,33.
Inspired by recently published biodegradable linear polymers
that were degraded by an acid-induced cascade reaction, we also
synthesized carbamate derivatives 3o–q (ref. 49). In this case,
4-hydroxybenzyl alcohol 10 was first protected with
tert-butyldimethylsilyl chloride to give compound 11 followed
by an esterification using 4-nitrophenyl chloroformiate. To trap
the excess of the chloroformiate, triethylene glycol monomethyl
ether was added49. The obtained carbonate 12 was then converted
with t-Boc-protected dimethylethylenediamine 13 and after
acid-catalysed cleavage of both protecting groups the
methylcarbamate 14 was isolated in 98% yield. Finally,
phenylcarbamates 15 were synthesized starting from 14 in an
one-pot reaction including tetramethylsilane (TMS) protection,
coupling with the corresponding acyl chloroformiates 16 and
desilylation in a yield of up to 59% (Fig. 2).
The 4-hydroxybenzyl alcohols bearing acyl-ester groups
at the phenol and the carbamates were converted into
phosphoramidites 5 in high yields as published before32,33.
Finally, d4TDP 6 was mixed with 1.7 equivalents (eq.) of a
corresponding phosphoramidite 5 and co-evaporated with
acetonitrile. Then, the mixture was dissolved in a minimum
of acetonitrile because achieving a high concentration was
crucial for the success of the coupling reaction. In case of
compounds with long acyl residues (RZC11H23),
tetrahydrofurane (THF) was added to accomplish complete
solubility of the reagents. In some cases, the conversion of
d4TDP 6 was not complete. In these cases, all volatile
components were removed in vacuum, the residue was
redissolved and further 1.0 eq. of the phosphoramidite 5 and
0.8 eq. of DCI were added. After another minute of stirring, the
reaction mixture was oxidized. After oxidation the quantitative
consumption of d4TDP 6 was confirmed using high-performance
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Figure 1 | Reagents and conditions. (i) Triethylamine, THF, 0 C-rt, 20 h; (ii) 1. 5-chlorosaligenylchlorophosphite 8, N,N-diisopropylethylamine, CH3CN,
 20 C-rt, 3 h, 2. t-BuOOH in n-decane, 0 C-rt, 30min; (iii) (H2PO4)Bu4N, DMF, rt, 20 h; (iv) 1. DCI, CH3CN, rt, 1min, 2. t-BuOOH in n-decane, 0 C-rt,
15min.
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liquid chromatography (HPLC; Supplementary Fig. 3). Next, the
solvent was removed in vacuum and the crude product was
purified with RP-18 chromatography using gradients of water/
acetonitrile or water/THF as eluents. For compounds 3a–f, l–n,
o–q the tetra-n-butylammonium ions were exchanged by
ammonium ions using Dowex 50WX8 and the chromatography
was repeated.
Synthesis of monomasked triphosphate prodrugs 4. In addition
to the TriPPPro-compounds 3, the monomasked acyloxybenzyl-
NTP derivatives 4 were synthesized as well (Fig. 3). Such
monoesterified substances were described by others as potential
triphosphate prodrugs38,39,50. Several synthesis routes mainly
based on DCC-activated coupling were published. In our recent
studies with DiPPro-prodrugs, we isolated such monoesterified
compounds by simple hydrolysis33.
An efficient access to such compounds was developed in this
study. The monoesterified NTPs were prepared starting from
4-acyloxybenzyl alcohol 9 and its conversion into the
5-nitro-cycloSal-triester 17. Despite the high reactivity of this
compound, the purification by preparative thin-layer chromato-
graphy (TLC) was successful. The benzyl-(5-nitro-cycloSal)-
phosphate triesters 17 were obtained in high yields (up to
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Figure 2 | Reagents and conditions. (i) TBDMSCl, imidazole, CH2Cl2, rt, 2 h; (ii) 1. 4-nitrophenyl chloroformiate, triethylamine, CH2Cl2, rt, 16 h, 2.
triethylene glycol monomethyl ether, rt, 20min; (iii) Boc2O, 0 C-rt, 20 h; (iv) 1. 4-DMAP, diisopropylethylamine, toluene, rt, 16 h, 2. TFA/CH2Cl2, rt, 0.5 h;
(v) 1. TMSCl, imidazole, THF, 0 C-rt, 2 h, 2. triethylamine, 0 C-rt, 1.5 h, 3. 1% HCl (12M) in EtOH, rt, 1 h.
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89%). Next, triesters 17 gave the monomasked acyloxybenzyl-
d4TTPs 4 in yields of 26–30% by the addition of d4TDP 6.
Stability studies. The TriPPPros-d4TTP prodrugs 3 and the
intermediates 4 were incubated in PBS (25mM, pH 7.3), or were
exposed to pig liver esterase (PLE) in PBS and to human CD4þ
T-lymphocyte cell extracts to study their stability and the product
distribution. The hydrolysis mixtures were analysed by means of
analytical RP-18-HPLC. The calculated half-lives (Table 1) were
determined for the first removal of one masking unit (t1/2(1)) to
yield the intermediate 4 and the second hydrolysis step (t1/2(2)) to
give the triphosphate 19.
Chemical stability in PBS at pH 7.3. In PBS, the stability of
TriPPPro-d4TTP prodrugs 3a–h,l–n increased with increasing
alkyl chain lengths (Table 1). However, the half-lives of more
lipophilic compounds 3i–k decreased because of altered
solubility behaviour or micelle formation. The half-lives of
the intermediates 4 were always considerably higher than those of
their precursors 3 because of the increase in charges leading to
repulsive interaction with an incoming nucleophile. Moreover,
formation of the three nucleotide forms 2, 6 and 19 were
observed (Supplementary Fig. 4).
Hydrolysis study using esterase. Next, we examined the enzy-
matic stability of prodrugs 3a–n by incubation with PLE in PBS,
pH 7.3. The cleavage of the masking units for 3b–g occurred
much faster than that in PBS, demonstrating a significant con-
tribution of the enzymatic cleavage (Table 1). As observed in the
chemical hydrolysis studies, the cleavage of the second masking
group proceeded much slower. According to the substrate spe-
cificity of PLE we determined the lowest half-lives for 3c–f and
3m. Shorter as well as longer alkyl residues in the ester moiety of
the masking group led to increased half-lives. In addition, d4TTP
19 was delivered by enzymatic activation of 3a–n but was also
found to be the sole metabolite from 4a,e,j as long as the
enzymatic cleavage occurred rapidly (Supplementary Fig. 5). The
carbamate-functionalized prodrugs 3o–q were not substrates for
PLE, as expected.
To confirm the prodrug concept and thus the direct successful
release of the biologically active triphosphate metabolite, the
prodrug 3e was exposed to PLE and the hydrolysis monitored
with RP-18-HPLC. After complete consumption of 3e as well as
its intermediate 4e the solvents were removed. For the template/
primer extension assay (Fig. 4a), HIV RT was incubated with the
PLE hydrolysate as such (T*) or with the PLE hydrolysate in the
additional presence of dCTP (T*, C), or dCTPþ dGTP (T*, C, G)
or all natural 20-deoxynucleotides (N*). Interestingly, an
immediate DNA chain termination was observed after
incorporation of d4TMP 2 (derived from the incoming d4TTP
19 that was released from the prodrug by PLE), while the
control reaction containing all four natural NTPs in the absence
of the PLE hydrolysate (N) showed full extension of the primer
(Fig. 4a). In addition, TriPPPro-TTP 3r was synthesized (Fig. 5)
and also investigated in the same way. As expected, the template/
primer extension assay showed efficient DNA elongation
(Fig. 4b). The T* lysate resulted in termination of the
polymerization because of the lack of the next complementary
nucleotide (dCTP; position 26 nt), whereas the reaction
proceeded till position 28 nt in the presence of both T* and
dCTP (T*, C). The primer could be fully extended till 30 nt
when T* was added in the presence of dCTP and dGTP, as also
the N* and N samples could.
Hydrolysis in cell extracts. The hydrolysis of the TriPPPro-
compounds 3 was further investigated in human CD4þ T-lym-
phocyte CEM cell extracts. Again, the half-lives of the prodrugs
3a–n correlated well with chain length and were significantly
lower than the half-lives in PBS buffer (Table 1). Thus, an
enzymatic cleavage reaction took place as described above for the
PLE studies. Furthermore, we observed the formation of the
corresponding intermediates 4a–n that had lower half-lives than
their parent prodrugs. This assumption was proven by hydrolysis
of the synthesized intermediates 4a,e,j. In contrast to hydrolysis
studies with PLE, in addition to d4TTP 19 d4TDP 6 was also
detected as a major component in the CEM cell extracts most
probably because of the presence of hydrolytic enzymes such as
phosphatases and esterases (Supplementary Fig. 6).
The formation of d4TDP 6 was clearly not a result of
unselective cleavage of the prodrug 3. Investigations in cell
Table 1 | Hydrolysis half-lives of TriPPPro-d4TTPs 3 and
monoesterified d4TTPs 4 in different media.
Compd R PBS, pH¼ 7.3 (h) PLE (h) CEM
(h)
t1/2(1)
* t1/2(2)
w t1/2(1)
* t1/2(2)
w t1/2(1)
*
3a CH3 18 75 1.9 71 0.050
3b C2H5 17 150 0.42 33 0.12
3c C4H9 22 270 0.063 7.7 0.43
3d C6H13 26 350 0.013 1.6 0.98
3e C8H17 52 390 0.013 1.6 2.5
3f C9H19 44 350 0.082 3.0 2.8
3g C11H23 68 410 0.95 8.3 2.2
3h C13H27 90 355 30 n.d.
z 4.6
3i C15H31 73 462 33 n.d.
z 5.3
3j C17H35 50 583 37 n.d.
z 13
3k C17H33 (8Z) 27 92 42 n.d.
z 4.3
3l OCH3 24 200 3.8 177 0.97
3m OC8H17 82 590 0.12 17 2.6
3n OC11H23 99 631 44 n.d.
z 3.0
3o NCH3(C9H19NO2) 27 n.d.
z n.d.y n.d.y n.d.z
3p NCH3(C13H27NO2) 48 n.d.
z n.d.y n.d.y 5.6
3q NCH3(C17H35NO2) 48 n.d.
z n.d.y n.d.y n.d.z
4a CH3 n.a.
|| 95 n.a.|| 108 0.040
4e C8H17 n.a.
|| 237 n.a.|| 1.5 1.8
4j C17H35 n.a.
|| 637 n.a.|| 57 4.6
*Half-lives of 3.
wHalf-lives of 4.
zNot determined.
yNo substrate for enzyme.
||Not available.
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Figure 4 | Primer extension assays with HIV reverse transcriptase.
(a) PLE hydrolysate based on TriPPPro-d4TTP 3e (T*); dCTP; dGTP; all
natural triphosphates (N); dATP, dCTP, dGTP and the hydrolysate of
3e (N*). (b) PLE hydrolysate based on TriPPPro-compound 3r (T*); dCTP;
dGTP; all natural triphosphates (N); dATP, dCTP, dGTP and the hydrolysate
of 3r (N*). nt: nucleotide, length of primer.
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extracts starting from d4TTP 19 led to a rapid degradation
(t1/2¼ 0.63 h). For this reason d4TDP 6 (t1/2¼ 59 h) accumulated
under these conditions. On the other hand, only very small
amounts of d4TMP 2 were formed. Nevertheless, it was proven
that the triphosphate of d4T 19 was successfully released in
biological media such as CD4þ T-lymphocyte extracts.
Antiviral evaluation. TriPPPro-compounds 3a–n were evaluated
for their ability to inhibit the replication of HIV. For this purpose,
HIV-1- or HIV-2-infected wild-type CEM/0 as well as mutant
TK-deficient CEM cell cultures (CEM/TK ) were treated with
the prodrugs 3. As can be seen in Table 1, all compounds showed
virtually similar activities against HIV-1 and HIV-2 as the parent
nucleoside d4T 1. A somewhat increased antiviral activity with
increasing lipophilicity resulting from their advantageous per-
meability was observed. In addition, all prodrugs with RZC8H17
were also highly potent in CEM/TK cells, whereas d4T 1 lacked
relevant anti-HIV activity as expected in this TK-deficient cell
model (EC50:150 mM). It should also be noticed that none of the
prodrugs 3 were endowed with a significantly higher cytotoxicity
than the parent d4T 1 compound (Table 2).
Discussion
We reported on the first successful direct intracellular delivery of
NTPs using prodrug technology. D4T triphosphate prodrugs
3a–q were prepared via a convergent route using phosphorami-
dite chemistry (Fig. 1). Despite complete and selective conversion,
TriPPPro-NTP prodrugs 3 were obtained in yields between 27
and 66%. We assumed that the loss in yield may be the result of a
cleavage of the b- and g-phosphate anhydride bond of the
prodrugs during work-up. This assumption was supported by the
detection of d4TDP 6 and the bis(benzyl)phosphate diester after
chromatography. Alternative purification methods such as
extraction and precipitation were investigated but proved to be
O
HO N
NH
O
O
O
HO N
NH
O
O
OH OAc
O
O N
NH
O
O
OAc
P
O
O
Cl
O
OdTP
O
O
O
P
O
HO
O
i
iii
iv
ii
O C8H17
O
O P
O
O
O P O P OdT
O O
O O
3× cat3r
20 21
22
2 2× (n-Bu)4N
+
––
–––
+
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rt, 17 h; (iv) 1. 5e, DCI, CH3CN, rt, 1min; 2. t-BuOOH in n-decane, 0 C-rt, 15min.
Table 2 | Antiviral activity and cytotoxicity of TriPPPro-d4TTPs 3 in comparison with the parent nucleoside d4T 1.
Compd EC50 (lM)* CC50 (lM)w
CEM CEM/TK CEM
HIV-1 HIV-2 HIV-2
3a 0.43±0.25 0.72±0.16 410 63±2
3b 0.46±0.21 1.16±0.15 410 57±6
3c 0.40±0.00 1.05±0.30 410 58±3
3d 0.36±0.06 0.94±0.16 10±0.00 74±2
3e 0.31±0.01 0.62±0.30 2.26±1.03 52±1
3f 0.25±0.07 0.33±0.03 0.50±0.14 34±5
3g 0.21±0.01 0.27±0.06 0.72±0.16 26±0
3h 0.50±0.14 1.10±0.23 1.63±0.52 28±7
3i 0.62±0.30 0.66±0.08 0.72±0.16 61±3
3j 0.17±0.00 0.31±0.00 0.28±0.04 29±9
3k 0.30±0.01 0.47±0.10 0.93±0.47 25±1
3l 0.40±0.00 0.92±0.12 410 16±1
3m 0.36±0.06 0.47±0.10 1.26±0.00 51±5
3n 0.50±0.14 0.69±0.21 1.26±0.00 41±12
d4T 0.33±0.11 0.89±0.00 150±9 79±3
*Antiviral activity in CD4þ T-lymphocytes: 50% effective concentration; values are the mean±s.d. of n¼ 2–3 independent experiments.
wCytotoxicity: 50% cytostatic concentration or compound concentration required to inhibit CD4þ T-cell (CEM) proliferation by 50%; values are the mean±s.d. of n¼ 2–3 independent experiments.
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inefficient. Nevertheless, by this method a large number of
TriPPPro-d4TTPs 3 bearing various acyloxybenzyl-masking units
were obtained. Moreover, this synthesis strategy also showed to
be applicable to the synthesis of TriPPPro-compounds bearing
other pyrimidine or purine nucleoside analogues. In addition, the
intermediates 4a,e,j were synthesized using the cycloSal method
and were obtained in moderate chemical yields. This method,
which is based on the cycloSal strategy, is a reliable method for the
synthesis of polyphosphate diesters comprising esters at both
ends of the polyphosphate group (Fig. 3)48,51,52.
In general, three reactions should be considered in the
hydrolysis pathways of TriPPPro-nucleotide prodrugs 3. First,
the designed pathway yielding the NTP; second, a concurrent
reaction that involved a nucleophilic reaction at the g-phosphate
leading to the formation of d4TDP 6; and third, a nucleophilic
reaction at the b-phosphate that would lead to d4TMP 2. Figure 6
summarizes all three possible hydrolysis pathways leading to the
different phosphorylated nucleotide species. As shown in Fig. 6,
to release d4TTP 19 two successive cleavage processes were
necessary (path A). Thus, in addition to hydrolysis pathway A,
also a reaction at the g- and b-phosphate groups took place as
side-reactions. Owing to the presence of a second energetically
rich pyrophosphate bond, but despite its additional negative
charge, the half-lives were found to be lower than those published
recently for the DiPPro-d4TDPs33. However, the triphosphate 19
was the predominant product formed (Supplementary Fig. 4).
Moreover, after the starting material 3e was completely
consumed, there was no further increase in the amounts of
d4TMP 2 and d4TDP 6, which again points to the fact that
the intermediate selectively delivers the triphosphate while the
mono- and the diphosphate are formed from the starting
TriPPPro-compounds only. A comparable behaviour has also
been observed for the DiPPro-compounds33.
In contrast, for the carbamate derivatives 3o–q the cleavage
of the masking groups occurred only once leading to the
intermediates 4o-q. Therefore, it was concluded that the delivery
mechanism should be different as compared with the
ester-bearing masking groups. Owing to the highly stable
carbamate functions present in the masking group, the first
masking group cannot be cleaved by the original mechanism that
involves a cleavage within the ester/carbamate residue. To gain
more insights into this, a hydrolysis experiment of derivative 3o
was conducted in 18O-labelled water to yield 4o. Surprisingly, the
18O-label was found in the cleaved benzyl-alcohol and not at the
phosphate, which was convincingly confirmed using mass
spectrometry (Supplementary Fig. 7). Two different interpreta-
tions are possible for this result: (i) a SN1-type reaction took place
forming a benzyl cation and the monomasked NTP intermediate
4. The cation is then trapped by addition of water or (ii) a
SN2-type reaction took place instead in which the labelled water
displaces the monomasked NTP intermediate 4 (Fig. 6, hydrolysis
pathway A2). In addition to hydrolysis in PBS, pH 7.3, 4p was
hydrolysed under slightly acidic conditions (pH 6.0), although in
comparison with the physiological pH conditions no difference in
its hydrolysis behaviour was observed. Because of the very long
hydrolysis time periods, a cleavage of the glycosidic bond in d4T
1 resulted in the appearance of the nucleobase thymine.
The amount doubles every 63 h; however, this aspect has not
been further considered in these investigations because it was
irrelevant in the enzyme or cell extract incubations and in the
case of other nucleoside analogues.
Finally, a very important result from the studies conducted
with the monomasked intermediates 4a,e,j was the finding that
exclusively d4TTP 19 was formed from these compounds.
In addition, the hydrolysis studies conducted in the presence of
PLE clearly led to the selective formation of two different NTPs
(d4TTP and TTP) from the corresponding prodrug forms.
In conclusion, because of a successful cell membrane passage of
the TriPPPro-compounds 3 and subsequent intracellular enzymatic
hydrolysis, which led to the direct intracellular formation of
phosphorylated d4T metabolites such as d4TTP 19 or at least
d4TDP 6, marked anti-HIV activity in CEM/TK cell cultures was
observed while the parent nucleoside d4T 1 lacked significant
activity in this cell assay. Thus, although the TriPPPro-compounds
are still charged at the phosphate groups, obviously the modifica-
tion at the g-phosphate group by lipophilic, bioreversible moieties
gives the molecule sufficient lipophilicity to penetrate the cell
membrane. To the best of our knowledge, we provided the first
direct proof of the successful application of masked triphosphates
that obviously are able to efficiently enter the cells and to directly
deliver a higher phosphate derivative, most likely d4TTP 19.
Because the concept should be generally applicable to natural
nucleosides and a broad variety of nucleoside analogues, a novel
way to deliver the corresponding bioactive triphosphate form of
these nucleosides without any need for further enzymatically
catalysed phosphorylation has been discovered. This concept seems
to be very interesting for application with nucleoside analogues that
show severe limitations in their activation to give the correspond-
ing NTPs. Moreover, we are convinced that this approach is not
limited to HIV treatment but can also be used for other viral targets
and cancer and can also be used as a delivery for non-natural NTPs
as biochemical tools in Chemical Biology approaches.
Methods
General. All reactions were carried out under dry conditions and at room
temperature. Solvents and reagents: Acetonitrile, THF and DMF were purchased
from Acros Organics (Extra Dry over molecular sieves) and dried with activated
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Figure 6 | Chemical hydrolysis pathways for TriPPPro-d4TTPs 3.
A1þ 2 delivery of d4TTP 19; B release of d4TDP 6 by cleavage of the
phosphoanhydride bond between b- and g-phosphate; C release of d4TMP
2 by cleavage of phosphoanhydride bond between a- and
b-phosphate.
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molecular sieves. Triethylamine and N,N-diisopropylethylamine were refluxed over
CaH2 for 3 days and distilled under nitrogen. 5-Chlorosaligenylchlorophosphite 8
and 5-nitrosaligenylchlorophosphite 18 were synthesized according to the litera-
ture and 8 freshly distilled before use48. All further reagents commercially available
were used as received. Thin-layer chromatography: For TLC Macherey–Nagel pre-
coated TLC sheets Alugram Xtra SIL G/UV254 were used; sugar-containing
compounds were visualized with sugar spray reagent (4-methoxybenzaldehyde/
EtOH/concentrated sulphuric acid/glacial acetic acid in ratio 5/90/5/0.1 v/v) and
phosphate-containing compounds with ammonium molybdate solution (1 g
(NH4)6Mo7O24 4 H2O in 7ml semiconcentrated nitric acid and 13ml water)
followed by tin(II)chloride solution (0.1 g SnCl2 2 H2O in 20ml 0.5mol l 1
hydrochloric acid). Preparative chromatography: The preparative TLCs were
accomplished with a chromatotron (Harrison Research, Model 7,924T) using glass
plates coated with 2 or 4mm layers of Merck 60 PF254 silica gel. Column
chromatography: Normal phase column chromatography was performed with
Macherey–Nagel silica gel 60M (0.04–0.063mm). Automatic RP-18
chromatography: For reverse-phase chromatography, an Intershim Puriflash 430 in
combination with Chromabond Flash RS40 C18ec was used. High-performance
liquid chromatography: HPLC was required for analytical studies and monitoring
reactions. It was performed using a VWR-Hitachi LaChromElite HPLC system
(L-2130, L-2200, L-2455) and EzChromElite software, equipped with a Nucleodur
100–5 C18ec or Nucleodur 100–5 C8ec (Macherey–Nagel). Acetonitrile for HPLC
was obtained from VWR (HPLC grade) and ultrapure water using Sartorius
Aurium pro (Sartopore 0.2 mm, UV detector). Tetra-n-butylammonium acetate
solution (2mM; TBAA, pH 6.3) or 10mM triethylammonium acetate (TEAA, pH
6.2) were used for buffering. Method A: Nucleodur 100–5 C18ec; 0–20min: TBAA
buffer/acetonitrile gradient (5–80%); 20–30min: buffer/acetonitrile (80%); 30–
33min: buffer/acetonitrile (80–5%); 33–38min: buffer/acetonitrile (5%); flow:
1mlmin 1. Method B: Nucleodur 100–5 C18ec; 0–20min: TEAA buffer/
acetonitrile gradient (5–90%); 20–30min: buffer/acetonitrile (90%); 30–33min:
buffer/acetonitrile (90–5%); 33–38min: buffer/acetonitrile (5%); flow: 1mlmin 1.
Method C: Nucleodur 100–5 C8ec; 0–25min: TBAA buffer/acetonitrile gradient
(5–80%); 25–30min: buffer/acetonitrile (80%); 30–33min: buffer/acetonitrile
(80–5%); 33–38min: buffer/acetonitrile (5%); flow: 1mlmin 1.
Nuclear Magnetic Resonance: NMR spectra were recorded at room temperature
in an automation mode with a Varian Gemini 2000BB, Bruker Fourier 300, Bruker
AMX 400, Bruker DRX 500 or Bruker AVIII 600. All 1H- and 13C-NMR chemical
shifts (d) are quoted in parts per million (p.p.m.) downfield from TMS and
calibrated on solvent signal. The 31P-NMR chemical shifts (proton decoupled) are
also quoted in p.p.m. using phosphoric acid as the external standard. Mass
spectrometry: high resolution mass spectrometry (HRMS and electrospray
ionization (ESI) mass spectra were acquired with a VG Analytical Finnigan
ThermoQuest MAT 95 XL spectrometer. MALDI measurements (matrix: 9-
aminoacridine (9AA)) were performed with a Bruker UltrafleXtreme spectrometer.
Infrared spectroscopy: IR spectra were recorded on a Bruker Alpha P FT-IR at room
temperature in the range of 400–4,000 cm 1.
General procedure A: preparation of 4-acyloxybenzyl alcohols 9. 4-Hydro-
xybenzyl alcohol 10 (1.1 eq.) and triethylamine (1.0 eq.) in THF were cooled down
to 0 C. The corresponding acyl chloride (1.0 eq.) in THF was added dropwise and
the mixture stirred for 1–2 h. The precipitate was removed by filtration and the
solvent evaporated in vacuum. The residue was diluted with CH2Cl2 and washed
once with saturated sodium bicarbonate solution and once with water. The organic
layer was dried with Na2SO4 and the solvent was removed in vaccum. The crude
material was purified using column chromatography to give compound 9.
The syntheses and characterization of 4-(hydroxymethyl)phenylalkanoates 9a-k
were described previously33.
4-(Hydroxymethyl)phenylmethylcarbonate 9l. General procedure A with 4.0 g
4-hydroxybenzyl alcohol 10 (33mmol, 1.1 eq.), 4.1ml triethylamine (3.0 g, 30mmol,
1.0 eq.) dissolved in 35ml THF and dropwise addition of 2.3ml methyl chlor-
oformate (2.8 g, 30mmol, 1.0 eq.) in 20ml THF at 0 C. Reaction time was 1.5 h at
room temperature (rt). Column chromatography (petroleum ether 50–70/ethyl
acetate 4:3 v/v). Yield: 4.6 g (25mmol, 85%) colourless oil. TLC (petroleum ether
50–70/ethyl acetate 3:2 v/v): Rf¼ 0.35; 1H-NMR (400MHz, dimethylsulphoxide
(DMSO)-d6): d 7.39–7.31 (m, 2H), 7.20–7.13 (m, 2H), 5.22 (t, J¼ 5.7Hz, 1H), 4.50
(d, J¼ 5.8Hz, 2H), 3.82 (s, 3H); 13C-NMR (101MHz, DMSO-d6): d 153.7, 149.5,
140.5, 127.5, 121.4, 62.3, 55.4; infrared red (IR): 3,375, 2,959, 2,873, 1,758, 1,254,
1,210 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd. for C9H10O4, 205.0471; found,
205.0337.
4-(Hydroxymethyl)phenyloctylcarbonate 9m. General procedure A with 3.1 g
4-hydroxybenzyl alcohol 10 (25mmol, 1.1 eq.), 3.1ml triethylamine (2.3 g,
23mmol, 1.0 eq.) dissolved in 35ml THF and dropwise addition of 4.4ml octyl
chloroformate (4.4 g, 23mmol, 1.0 eq.) in 20ml THF at 0 C. Reaction time was
1.5 h at rt. Column chromatography (petroleum ether 50–70/ethyl acetate 4:3 v/v).
Yield: 5.3 g (19mmol, 84%) colourless oil. TLC (PE/EE 3:1 v/v): Rf¼ 0.45; 1H-NMR
(300MHz, DMSO-d6): d 7.39–7.31 (m, 2H), 7.21–7.12 (m, 2H), 5.22 (t, J¼ 5.7Hz,
1H), 4.49 (d, J¼ 5.7Hz, 2H), 4.18 (t, 3JHH¼ 6.6Hz, 2H), 1.72–1.58 (m, 2H),
1.41–1.18 (m, 10H), 0.87 (t, J¼ 6.7Hz, 3H); 13C-NMR (75MHz, DMSO-d6):
d 153.2, 149.5, 140.4, 127.5, 120.8, 68.5, 62.3, 31.2, 28.6, 28.0, 25.2, 22.1, 28.6, 14.0;
IR: 3,377, 2,955, 2,856, 1,758, 1,247, 1,210 cm 1; HRMS (ESIþ , m/z): [MþNa]þ
calcd. for C16H24O4, 303.1567; found, 303.1568.
4-(Hydroxymethyl)phenyldodecylcarbonate 9n. General procedure A with
4.1 g 4-hydroxybenzyl alcohol 10 (33mmol, 1.1 eq.), 4.0ml triethylamine (2.9 g,
30mmol, 1.0 eq.) dissolved in 40ml THF and dropwise addition of 8.1ml dodecyl
chloroformate (7.5 g, 30mmol, 1.0 eq.) in 20ml THF at 0 C. Reaction time was
1.5 h at rt. Column chromatography (petroleum ether (PE) 50–70/ethyl acetate
(EE) 4:1 v/v). Yield: 7.7 g (23mmol, 76%) colourless oil. TLC (PE/EE 3:1 v/v):
Rf¼ 0.48; 1H-NMR (300MHz, CDCl3): d 7.42–7.33 (m, 2H), 7.21–7.12 (m, 2H),
4.68 (s, 2H), 4.24 (t, J¼ 6.7Hz, 2H), 1.81–1.69 (m, 2H), 1.47–1.19 (m, 18H), 0.88 (t,
J¼ 6.7Hz, 3H); 13C-NMR (75MHz, CDCl3): d 153.9, 150.7, 138.8, 128.2, 121.1,
69.2, 64.8, 32.1, 29.8, 29.7, 29.6, 29.5, 29.3, 28.7, 25.8, 22.8, 28.6, 14.3; IR: 3,355,
2,917, 2,848, 1,747, 1,273 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd. for
C20H34O4, 359.2193; found, 359.2195.
4-(((tert-Butyldimethylsilyl)oxy)methyl)phenol 11. 4-Hydroxybenzyl alcohol
10 (5.1 g; 41mmol, 1.0 eq.), dissolved in 40ml DMF, was converted with 6.8 g
tert-butyldimethylsilyl chloride (45mmol, 1.1 eq.) and 6.1 g imidazole (89mmol,
2.2 eq.). After 17 h the solvent was removed by evaporation. The crude product was
dissolved in CH2Cl2 and washed with 0.1M HCl. The organic phase was dried over
Na2SO4, filtered and the solvent was removed by evaporation. Column chroma-
tography (petroleum ether 50–70/ethyl acetate 6:1 v/v). Yield: 7.9 g (33mmol, 81%)
colourless oil. TLC (PE/EE 4:1 v/v): Rf¼ 0.34; 1H-NMR (300MHz, DMSO-d6):
d 9.28 (s, 1H), 7.12–7.06 (m, 2H), 6.74–6.68 (m, 2H), 4.56 (s, 2H), 0.87 (s, 9H), 0.04
(s, 6H); 13C-NMR (75MHz, DMSO-d6): d 139.2, 131.6, 127.5, 114.6, 64.0, 25.6,
17.6,  5.4; IR: 3,355, 2,954, 2,857, 1,707, 1,515 cm 1; HRMS (ESIþ , m/z):
[MþNa]þ calcd. for C13H22O2Si, 261.1287; found, 261.1285.
4-(((tert-Butyldimethylsilyl)oxy)methyl)phenyl-(4-nitrophenyl)-carbonate 12.
Compound 11 (7.6 g; 32mmol, 1.0 eq.) was dissolved in 100ml CH2Cl2.
4-Nitrophenyl chloroformate (12.8 g; 64mmol, 2.0 eq.) was added slowly to the
reaction flask and the mixture was kept for 1 h at rt. Then, for consumption of the
excess of chloroformate and for facilitation of purification, 7.5ml tri(ethylene
glycol) monomethyl ether (7.9 g, 48mmol, 1.5 eq.) was added. After 20min the
solution was diluted with CH2Cl2 and washed with 1M HCl. The organic phase
was dried over Na2SO4, filtered and the solvent was removed by evaporation.
Column chromatography (petroleum ether 50–70/ethyl acetate 6:1 v/v). Yield: 6.8 g
(17mmol, 53%) colourless solid. TLC (PE/EE 6:1 v/v): Rf¼ 0.73; 1H-NMR
(400MHz, DMSO-d6): d 8.38–8.33 (m, 2H), 7.73–7.67 (m, 2H), 7.43–7.36 (m, 4H),
4.73 (s, 2H), 0.91 (s, 9H), 0.09 (s, 6H); 13C-NMR (101MHz, DMSO-d6): d 155.2,
150.7, 149.3, 145.4, 139.6, 127.2, 125.4, 122.7, 120.9, 63.6, 25.8, 18.0,  5.3; IR:
2,954, 2,929, 2,857, 1,768, 1,265 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd. for
C20H25NO6Si, 426.1349; found, 426.1340.
tert-Butylmethyl(2-(methylamino)ethyl)-carbamate 13. A flask containing
4.6ml N,N´-dimethylethylendiamine (3.7 g, 42mmol, 3.8 eq.) in 40ml CH2Cl2 was
cooled to 0 C. A solution of 2.4 g di-tert-butyl dicarbonate (11mmol, 1.0 eq.) in
20ml CH2Cl2 was added dropwise and, following the reaction mixture, was allowed
to warm to rt. After 16 h, the solvent was removed in vacuum. The product was
extracted with ethyl acetate/water (2:1 v/v) and washed with saturated aqueous
NaHCO3. The organic phase was dried over Na2SO4, filtered and the solvent was
removed by evaporation. Yield: 1.6 g (8.6mmol, 78%) yellowish oil. 1H-NMR
(600MHz, CDCl3): d 3.35–3.25 (m, 2H, rotamers), 2.85 (s, 3H), 2.70 (t, J¼ 6.7Hz,
2H), 2.42 (s, 3H), 1.43 (s, 9H); 13C-NMR (151MHz, CDCl3): d 156.1, 79.5, 49.8,
48.8þ 48.3 (rotamers), 36.4, 34.9þ 34.8 (rotamers), 28.6; IR: 2,974, 2,931, 1,687,
1,154 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd. for C9H20N2O2, 211.1417;
found, 211.1411.
4-(Hydroxymethyl)phenyl-methyl(2-(methylamino)ethyl)-carbamate 14. At
0 C to a stirred solution of 1.6 g compound 13 (8.6mmol, 1.2 eq.), 1.9ml
diisopropylethylamine (1.4 g, 11mmol, 1.6 eq.) and catalytic amounts of 4-dime-
thylaminophenol in 30ml toluene 2.8 g activated carbonate 12 (7.0mmol, 1.0 eq.)
was added. The reaction mixture was allowed to warm to rt and stirred for 16 h.
The solution was diluted with ethyl acetate and washed with 1M HCl, followed by
saturated aqueous NaHCO3. The organic phase was dried over Na2SO4, filtered and
the solvent was removed by evaporation. For deprotection the residue was redis-
solved in a mixture of CH2Cl2/trifluoroacetic acid (1:1 v/v). After 1 h the volatile
components were removed by evaporation and the residue was co-evaporated twice
with toluene. The crude material was purified by automatic RP-18 chromatography
(water/acetontrile gradient). Yield: 1.6 g (6.9mmol, 98%) yellowish oil. TLC
(CH2Cl2/MeOH 4:1 v/v): Rf¼ 0.67; 1H-NMR (400MHz, DMSO-d6): d 8.72, 8.62
(br.s, 2H, rotamers), 7.34–7.28 (m, 2H), 7.14–7.07 (m, 2H), 4.48 (s, 2H), 3.69, 3.57
(t, J¼ 6.0Hz, 2H, rotamers), 3.24–3.10 (m, 2H, rotamers), 3.05, 2.93 (s, 3H,
rotamers), 2.68–2.57 (m, 3H, rotamers); 13C-NMR (101MHz, DMSO-d6):
d 154.7þ 153.8 (rotamers), 149.9, 139.7, 127.2, 121.7þ 121.4 (rotamers), 62.4,
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46.3þ 46.0 (rotamers), 45.2, 34.6þ 34.4 (rotamers), 32.9þ 32.8 (rotamers); IR:
3,401, 2,975, 2,871, 1,671, 1,172 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd.
for C12H18N2O3, 239.1390; found, 239.1391.
General procedure B: preparation of bis-methylcarbamates 15. 4-(Hydro-
xymethyl)phenylcarbamate 14 (1.0 eq.) was dissolved in THF and cooled down to
0 C. After addition of imidazole (1.3 eq.) and TMSCl (1.2 eq.) the mixture was
stirred for 2 h. Triethylamine (3.1 eq.) and the corresponding alkyl chloroformate
(3.0 eq.) were added. The reaction was kept for 1.5 h at rt and then diluted with
30ml of 1 vol% concentrated (12M) HCl in EtOH for desilylation. The solution
was stirred for 1 h and the solvent evaported in vacuum. The residue was dissolved
in CH2Cl2 and washed with saturated aqueous NaHCO3. The organic phase was
dried over Na2SO4, filtered and the solvent was removed in vacuum. The crude
material was purified using column chromatography.
n-Butyl-(4-(hydroxymethyl)phenyl)ethane-1,2-diylbis(methylcarbamate) 15o.
General procedure B with 2.1 g 14 (8.8mmol, 1.0 eq.), 0.78 g imidazole (11mmol,
1.3 eq.), 1.3ml TMSCl (1.1 g, 11mmol, 1.2 eq.), 3.8ml triethylamine (2.8 g,
27mmol, 3.1 eq.), 3.4ml butyl chloroformate (3.6 g, 26mmol, 3.0 eq.) dissolved in
15ml THF. Column chromatography (petroleum ether 50–70/ethyl acetate 1:1 v/v).
Yield: 1.8 g (19mmol, 59%) colourless oil. TLC (CH2Cl2/MeOH 9:1 v/v): Rf¼ 0.56;
1H-NMR (400MHz, DMSO-d6): d 7.34–7.27 (m, 2H), 7.04–6.97 (m, 2H), 5.17
(t, J¼ 5.6Hz, 1H), 4.48 (d, J¼ 4.3Hz, 2H), 4.02–3.91 (m, 2H), 3.57–3.40
(m, 4H, rotamers), 3.02, 2.90 (s, 3H, rotamers), 2.90–2.82 (m, 3H, rotamers),
1.60–1.44 (m, 2H, rotamers), 1.39–1.22 (m, 2H, rotamers), 0.87, 0.80 (t, J¼ 7.3Hz,
3H, rotamers); 13C-NMR (101MHz, DMSO-d6): d 155.8, 153.9, 150.0, 139.3, 127.2,
121.4þ 121.3 (rotamers), 64.5þ 64.4 (rotamers), 62.4, 46.5þ 46.2 (rotamers),
46.0þ 45.6 (rotamers), 35.2þ 35.0 (rotamers), 34.7þ 34.5 (rotamers), 30.6þ 30.6
(rotamers), 18.6, 13.6; IR: 3,445, 2,958, 2,933, 1,694, 1,202 cm 1; HRMS (ESIþ ,
m/z): [MþH]þ calcd. for C17H26N2O5, 339.1914; found, 339.1918.
n-Octyl-(4-(hydroxymethyl)phenyl)ethane-1,2-diylbis(methylcarbamate) 15p.
General procedure B with 0.86 g 14 (3.6mmol, 1.0 eq.), 0.32 g imidazole (4.7mmol,
1.3 eq.), 0.55ml TMSCl (0.47 g, 4.3mmol, 1.2 eq.), 1.6ml triethylamine (1.1 g,
11mmol, 3.1 eq.), 2.1ml octyl chloroformate (2.1 g, 11mmol, 3.0 eq.) dissolved in
5ml THF. Column chromatography (petroleum ether 50–70/ethyl acetate 1:1 v/v).
Yield: 0.72 g (1.8mmol, 51%) colourless oil. TLC (CH2Cl2/MeOH 9:1 v/v):
Rf¼ 0.60; 1H-NMR (400MHz, DMSO-d6): d 7.34–7.27 (m, 2H), 7.02–6.98 (m, 2H),
5.17 (t, J¼ 5.7Hz, 1H), 4.47 (d, J¼ 5.6Hz, 2H), 4.01–3.90 (m, 2H), 3.57–3.39
(m, 4H, rotamers), 3.02, 2.90 (s, 3H, rotamers), 2.90–2.81 (m, 3H, rotamers),
1.62–1.44 (m, 2H, rotamers), 1.36–1.12 (m, 10H), 0.89–0.80 (m, 3H, rotamers);
13C-NMR (101MHz, DMSO-d6): d 155.7, 154.0, 150.0, 139.2, 127.2, 121.4þ 121.3
(rotamers), 64.8þ 64.7 (rotamers), 62.4, 46.5þ 46.2 (rotamers), 45.9þ 45.5
(rotamers), 34.6þ 34.5 (rotamers), 31.2, 28.7, 28.6þ 28.6 (rotamers), 25.4, 22.0,
13.9; IR: 3,447, 2,926, 2,856, 1,698, 1,203 cm 1; HRMS (ESIþ , m/z): [MþH]þ
calcd. for C21H34N2O5, 395.2540; found, 395.2540.
n-Dodecyl-(4-(hydroxymethyl)phenyl)ethane-1,2-diylbis(methylcarbamate) 15q.
General procedure B with 0.95 g 14 (4.0mmol, 1.0 eq.), 0.35 g imidazole (5.2mmol,
1.3 eq.), 0.61ml TMSCl (0.52 g, 4.8mmol, 1.2 eq.), 1.7ml triethylamin (1.3 g,
12mmol, 3.1 eq.), 3.2ml dodecyl chloroformate (3.0 g, 12mmol, 3.0 eq.) dissolved
in 15ml THF. Column chromatography (petroleum ether 50–70/ethyl acetate 1:1 v/
v). Yield: 0.75 g (1.7mmol, 42%) colourless oil. TLC (CH2Cl2/MeOH 9:1 v/v):
Rf¼ 0.65; 1H-NMR (400MHz, CDCl3): d (p.p.m.)¼ 7.36–7.31 (m, 2H), 7.10–7.05
(m, 2H), 4.64 (s, 2H), 4.12–4.02 (m, 2H), 3.63–3.44 (m, 4H, rotamers), 3.15–2.89 (s,
6H, rotamers), 1.68–1.54 (m, 2H, rotamers), 1.43–1.13 (m, 10H), 0.88 (t, J¼ 6.8Hz,
3H); 13C-NMR (101MHz, CDCl3): d 157.1, 154.9, 151.0, 138.3, 128.0,
121.9þ 121.3 (rotamers), 65.9þ 65.8 (rotamers), 64.9, 47.4þ 47.3 (rotamers),
47.1þ 46.4 (rotamers), 35.4þ 35.3 (rotamers), 32.1, 29.8, 29.7, 29.7, 29.5þ 29.5
(rotamers), 29.4, 29.2, 29.2, 26.1, 22.8, 14.2; IR: 3,459, 2,923, 1,699, 1,203 cm 1;
HRMS (ESIþ , m/z): [MþH]þ calcd. for C25H42N2O5, 451.3172; found, 451.3167.
General procedure C: preparation of bis-(4-acyloxybenzyl)-N,N-diisopropyl-
phosphoramidites 5. Dichloro-N,N-diisopropylphosphoramidite (1.0 eq.) was
dissolved in THF and cooled to 0 C. Triethylamine (2.3 eq.) and the corresponding
4-acyloxybenzylalcohol 9 (2.1–2.2 eq.) in THF were added dropwise. The reaction
mixture was kept at 0 C for 18–24 h. After filtration, the solvent was removed by
evaporation. The crude products were purified either using column chromato-
graphy or using preparative TLC (chromatotron).
The syntheses and characterization of Bis-(4-acyloxybenzyl)-N,N-diisopropyl-
phosphoramidite 5a–k were described previously33.
Bis-(4-methyloxycarbonyloxybenzyl)-N,N-diisopropylaminophosphoramidite 5l.
General procedure C with 0.74 g dichloro-N,N-diisopropylphosphoramidite
(3.7mmol, 1.0 eq.) dissolved in 15ml THF, 1.2ml triethylamine (0.85 g, 8.4mmol,
2.3 eq.) and 1.5 g 4-(hydroxymethyl)phenylmethylcarbonate (8.2mmol, 2.2 eq.) in
15ml THF. The crude product was purified by preparative TLC (petroleum ether
50–70/ethyl acetate 4:1 v/vþ 5% Et3N). Yield: 1.5 g (3.0mmol, 82%) colourless oil.
TLC (PE/EE 1:1 v/vþ 5% Et3N): Rf¼ 0.77; 1H-NMR (300MHz, DMSO-d6): d
7.42–7.34 (m, 4H), 7.18–7.07 (m, 4H), 4.78–4.61 (m, 4H), 3.82 (s, 6H), 3.72–3.57
(m, 2H), 1.16 (d, J¼ 6.8Hz, 12H); 13C-NMR (75MHz, DMSO-d6): d 153.7, 149.9,
137.2 (d, J¼ 7.4Hz), 128.0, 121.1, 64.1 (d, J¼ 18.1Hz), 55.4, 42.6 (d, J¼ 12.5Hz),
24.4 (d, J¼ 6.7Hz); 31P-NMR (202MHz, DMSO-d6): d 147.5; IR: 2,965, 2,916,
1,760, 1,200, 1,126 cm 1; HRMS (ESIþ , m/z): [MþH]þ calcd. for C24H32NO8P,
494.1938; found, 494.2276.
Bis-(4-octyloxycarbonyloxybenzyl)-N,N-diisopropylaminophosphoramidite 5m.
General procedure C with 0.76 g dichloro-N,N-diisopropylphosphoramidite
(3.8mmol, 1.0 eq.) dissolved in 15ml THF, 1.3ml triethylamine (0.88 g, 8.7mmol,
2.3 eq.) and 2.3 g 4-(hydroxymethyl)phenyloctylcarbonate (8.3mmol, 2.2 eq.) in
15ml THF. The crude product was purified by preparative TLC (petroleum ether
50–70/ethyl acetate 6:1 v/vþ 5% Et3N). Yield: 2.2 g (3.2mmol, 83%) colourless oil.
TLC (PE/EE 6:1 v/vþ 5% Et3N): Rf¼ 0.43; 1H-NMR (300MHz, CDCl3):
d 7.39–7.31 (m, 4H), 7.20–7.13 (m, 4H), 4.80–4.62 (m, 4H), 4.24 (t, J¼ 6.7Hz, 4H),
3.69 (dquint, J¼ 10.0Hz, J¼ 6.8Hz, 2H), 1.82–1.66 (m, 4H), 1.48–1.23 (m, 16H),
1.20 (d, J¼ 6.8Hz, 12H), 0.89 (t, J¼ 6.7Hz, 6H); 13C-NMR (75MHz, CDCl3):
d 153.9, 150.4, 137.4 (d, J¼ 7.5Hz), 128.2, 121.0, 69.1, 64.9 (d, J¼ 18.7Hz), 42.2
(d, J¼ 12.6Hz), 31.9, 29.3, 29.3, 25.8, 22.8, 28.7, 24.8 (d, J¼ 7.6Hz), 14.2; 31P-NMR
(202MHz, CDCl3): d 148.0; IR: 2,961, 2,926, 1,759, 1,215 cm 1; HRMS (ESIþ ,
m/z): [MþH]þ calcd. for C38H60NO8P, 690.4129; found, 690.4086.
Bis-(4-dodecyloxycarbonyloxybenzyl)-N,N-diisopropylaminophosphoramidite 5n.
General procedure C with 0.50 g dichloro-N,N-diisopropylphosphoramidite
(2.5mmol, 1.0 eq.) dissolved in 14ml THF, 0.80ml triethylamine (0.58 g, 5.8mmol,
2.3 eq.) and 1.8 g 4-(hydroxymethyl)phenyldodecylcarbonate (5.2mmol, 2.1 eq.) in
10ml THF. The crude product was purified using preparative TLC (petroleum
ether 50–70/ethyl acetate 10:1 v/vþ 5% Et3N). Yield: 1.8 g (2.2mmol, 88%) col-
ourless solid. TLC (PE/EE 6:1 v/vþ 5% Et3N): Rf¼ 0.53; 1H-NMR (300MHz,
CDCl3): d 7.39–7.32 (m, 4H), 7.17–7.09 (m, 4H), 4.80–4.62 (m, 4H), 4.24 (t,
J¼ 6.7Hz, 4H), 3.75–3.57 (m, 2H), 1.80–1.67 (m, 4H), 1.47–1.23 (m, 36H), 1.20
(d, J¼ 6.8Hz, 12H), 0.88 (t, J¼ 6.7Hz, 6H); 13C-NMR (75MHz, CDCl3): d 153.9,
150.4, 137.4 (d, J¼ 7.8Hz), 128.2, 121.0, 69.1, 64.9 (d, J¼ 18.2Hz), 43.2
(d, J¼ 12.5Hz), 32.1, 29.8, 29.7, 29.6, 29.5, 29.4, 25.8, 22.8, 28.6, 24.8 (d, J¼ 7.4Hz),
14.3; 31P-NMR (162MHz, CDCl3): d 148.0; IR: 2,961, 2,923, 2,853, 1,760,
1,216 cm 1; HRMS (ESIþ , m/z): [MþH]þ calcd. for C46H76NO8P, 802.5381;
found, 802.5352.
Bis-(4-(butyl-ethan-1,2-diylbis(methylcarbamate))-oxybenzyl)-N,N-diisopro-
pylaminophosphoramidite 5o. General procedure C with 0.20 g dichloro-N,N-
diisopropylphosphoramidite (0.99mmol, 1.0 eq.) dissolved in 4ml THF, 0.32ml
triethylamine (0.23 g, 2.3mmol, 2.3 eq.) and 0.75 g compound 15o (2.2mmol,
2.2 eq.) in 5ml THF. The crude product was purified using column chromato-
graphy (petroleum ether 50–70/ethyl acetate 1:1 v/vþ 5% Et3N). Yield: 0.49 g
(0.61mmol, 62%) colourless oil. TLC (PE/EE 1:1 v/vþ 5% Et3N): Rf¼ 0.30;
1H-NMR (400MHz, CDCl3): d 7.39–7.30 (m, 4H), 7.10–7.01 (m, 4H), 4.78–4.60
(m, 4H), 4.14–4.02 (m, 4H), 3.76–3.61 (m, 2H), 3.62–3.42 (m, 8H, rotamers),
3.15–2.89 (m, 12H, rotamers), 1.65–1.56 (m, 4H, rotamers), 1.46–1.30 (m, 4H,
rotamers), 1.19 (d, J¼ 6.9Hz, 12H), 0.93, 0.88 (t, J¼ 7.4Hz, 6H, rotamers);
13C-NMR (101MHz, CDCl3): d 156.9, 154.8, 150.5, 136.5, 128.0, 121.6þ 121.6
(rotamers), 65.7þ 65.6 (rotamers), 65.0 (d, J¼ 18.1Hz), 47.8þ 47.4 (rotamers),
47.0þ 46.4 (rotamers), 43.3 (d, J¼ 12.2Hz), 35.4þ 35.3 (rotamers), 35.2þ 34.8
(rotamers), 31.3þ 31.3 (rotamers), 24.8 (d, J¼ 7.5Hz), 19.3, 13.9; 31P-NMR
(162MHz, CDCl3): d 147.4; IR: 2,962, 2,932, 2,871, 1,719, 1,695, 1,199 cm 1;
HRMS (ESIþ , m/z): [MþH]þ calcd. for C40H64N5O10P, 806.4464; found,
806.4440.
Bis-(4-(octyl-ethan-1,2-diylbis(methylcarbamate))-oxybenzyl)-N,N-diisopro-
pylaminophosphoramidite 5p. General procedure C with 0.14 g dichloro-N,N-
diisopropylphosphoramidite (0.71mmol, 1.0 eq.) dissolved in 10ml THF, 0.23ml
triethylamine (0.17 g, 1.6mmol, 2.3 eq.) and 0.59 g compound 15p (1.5mmol,
2.1 eq.) in 5ml THF. The crude product was purified using column chromato-
graphy (petroleum ether 50–70/ethyl acetate 1:1 v/vþ 5% Et3N). Yield: 0.59 g
(0.64mmol, 90%) colourless oil. TLC (PE/EE 1:1 v/vþ 5% Et3N): Rf¼ 0.41;
1H-NMR (400MHz, CDCl3): d 7.37–7.29 (m, 4H), 7.10–7.02 (m, 4H), 4.78–4.61
(m, 4H), 4.12–4.02 (m, 4H), 3.74–3.63 (m, 2H), 3.62–3.43 (m, 8H, rotamers),
3.15–2.89 (m, 12H, rotamers), 1.69–1.55 (m, 4H, rotamers), 1.40–1.19 (m, 36H,
rotamers), 1.19 (d, J¼ 6.8Hz, 12H), 0.87 (t, J¼ 6.8Hz, 6H, H-n, rotamers);
13C-NMR (101MHz, CDCl3): d 156.6, 154.8, 150.7, 136.6, 128.0, 121.6þ 121.5
(rotamers), 65.9þ 65.8 (rotamers), 65.0 (d, J¼ 18.0Hz), 47.6þ 47.4 (rotamers),
47.0þ 46.4 (rotamers), 43.2 (d, J¼ 12.6Hz), 35.4þ 35.3 (rotamers), 35.1þ 34.8
(rotamers), 31.9, 29.4, 29.3, 29.2þ 29.2 (rotamers), 26.1, 24.8 (d, J¼ 7.2Hz), 22.8,
14.2; 31P-NMR (162MHz, CDCl3): d 147.7; IR: 2,958, 2,927, 2,856, 1,722, 1,699,
1,202 cm 1; HRMS (ESIþ , m/z): [MþH]þ calcd. for C48H80N5O10P, 918.5716;
found, 918.6124.
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Bis-(4-(dodecyl-ethan-1,2-diylbis(methylcarbamate))-oxybenzyl)-N,N-diiso-
propylaminophosphoramidite 5q. General procedure C with 0.15 g dichloro-
N,N-diisopropylphosphoramidite (0.75mmol, 1.0 eq.) dissolved in 3ml THF,
0.24ml triethylamine (0.17 g, 1.7mmol, 2.3 eq.) and 0.71 g compound 15q
(1.6mmol, 2.1 eq.) in 5ml THF. The crude product was purified using column
chromatography (petroleum ether 50–70/ethyl acetate 1:1 v/vþ 5% Et3N). Yield:
0.37 g (0.36mmol, 48%) colourless oil. TLC (PE/EE 1:1 v/vþ 5% Et3N): Rf¼ 0.50;
1H-NMR (600MHz, CDCl3): d 7.36–7.30 (m, 4H), 7.08–7.03 (m, 4H), 4.76–4.62
(m, 4H), 4.11–4.02 (m, 4H), 3.73–3.62 (m, 2H), 3.61–3.42 (m, 8H, rotamers),
3.14–2.90 (m, 12H, rotamers), 1.67–1.56 (m, 4H, rotamers), 1.37–1.21 (m, 36H),
1.19 (d, J¼ 6.8Hz, 12H), 0.87 (t, J¼ 6.9Hz, 6H, rotamers); 13C-NMR (101MHz,
CDCl3): d 157.0, 154.7, 150.7þ 150.6 (rotamers), 136.6, 128.0þ 128.0 (d, J¼ 2.6
Hz), 121.6þ 121.5 (rotamers), 65.9þ 65.8 (rotamers), 65.0 (d, J¼ 18.3Hz),
47.4þ 47.3 (rotamers), 46.9þ 46.4 (rotamers), 43.2 (d, J¼ 12.3Hz), 35.4, 35.3
(rotamers), 35.0þ 34.6 (rotamers), 32.0, 29.8, 29.7, 29.7, 29.7, 29.5, 29.4,
29.2þ 29.2 (rotamers), 26.1, 24.8 (d, J¼ 7.4Hz), 22.8, 14.2; 31P-NMR (162MHz,
CDCl3): d 147.3; IR: 2,923, 2,853, 1,721, 1,699, 1,200 cm 1; HRMS (ESIþ , m/z):
[MþH]þ calcd. for C48H80N5O10P, 1030.6982; found, 1030.6968.
5-Chloro-cycloSal-30-deoxy-20,30-didehydrothymidine monophosphate 7.
To a suspension of 0.50 g d4T 1 (2.2mmol, 1.0 eq.) in 8ml, acetonitrile was
added 0.53ml diisopropylethlyamine (0.54 g, 3.1mmol, 1.4 eq.) followed by 0.60 g
5-chlorosaligenylchlorophosphite 8 (2.7mmol, 1.2 eq.). The reaction mixture was
stirred for 3 h and subsequently cooled to 0 C. By addition of a 5.5-M solution of
0.57ml tert-butylhydroperoxide in n-decane (3.1mmol, 1.4 eq.) the phosphite was
oxidized for 20min. The solvent was removed in vacuum. The residue was
redissolved in CH2Cl2 and washed with 1M ammonium acetate solution. The
organic phase was dried over Na2SO4, filtered and the solvent was removed by
evaporation. The crude product was purified using column chromatography
(CH2Cl2/MeOH 9:1 v/v). Yield: 0.91 g (2.1mmol, 97%) colourless foam as a
mixture of two diastereomers. TLC (CH2Cl2/MeOH 9:1 v/v): Rf¼ 0.29; 1H-NMR
(500MHz, CDCl3): d 8.92, 8.92 (br.s, 1H, diasteromers), 7.33–7.26 (m, 1H, ds),
7.20, 7.18 (s, 1H, ds), 7.12–7.07 (m, 1H, ds), 7.04–6.95 (m, 2H, ds), 6.40–6.32
(m, 1H, ds), 5.94, 5.94 (d, J¼ 5.8Hz, ds), 5.43–5.18 (m, 2H, ds), 5.06–4.99
(m, 1H, ds), 4.47–4.30 (m, 2H, ds), 1.82, 1.73 (s, 3H, ds); 13C-NMR (126MHz,
CDCl3): d 163.9þ 163.8 (diastereomers), 150.9þ 150.8 (ds), 148.7þ 148.7 (ds),
135.8þ 135.6 (ds), 132.8þ 132.7 (ds), 130.3þ 130.3 (ds), 130.1þ 130.1 (ds),
128.1þ 128.0 (ds), 125.7þ 125.6 (ds), 122.3þ 122.3 (ds), 120.1þ 120.0 (d,
J¼ 5.3Hz, ds), 111.5þ 111.4 (ds), 90.0þ 89.9 (ds), 84.6þ 84.5 (ds), 68.7þ 68.6
(ds), 68.1þ 67.9 (d, J¼ 6.7Hz, ds), 12.4þ 12.3 (ds); 31P-NMR (162MHz, CDCl3):
d  9.80,  9.87 (s, diastereomers); IR: 3,168, 3,050, 2,886, 1,684 cm 1; HRMS
(ESIþ , m/z): [MþH]þ calcd. for C17H16ClN2O7P, 449.0276; found, 449.0287.
30-Deoxy-20,30-didehydrothymidinediphosphate 6 (d4TDP, tetra-n-buty-
lammonium salt). cycloSal-triester 7 (1.1 g; 2.5mmol, 1.0 eq.) was dissolved in
10ml DMF and added dropwise to a solution of 2.1 g mono-(tetra-n-buty-
lammonium)-phosphate (6.2mmol, 2.5 eq.) in 12ml DMF. After 16 h, the solvent
was removed in vacuum. The residue was extracted with ethyl acetate/water
followed by freeze-drying of the aqueous phase. The crude product was purified
using automatic RP-18 chromatography (water/acetonitrile gradient: 5–100%,
0–90min, flow 1mlmin 1). The purification had to repeat for complete
removement of the excess of the monophosphate salt. Yield: 0.78 g (0.90mmol,
36%, 2 Bu4Nþ ) colourless solid. TLC (isopropanol/NH3/water 4:1:2.5 v/v/v):
Rf¼ 0.16; 1H-NMR (300MHz, D2O): d 7.60 (d, J¼ 1.3Hz, 1H), 6.93 (dt, J¼ 3.3Hz,
J¼ 1.7Hz, 1H), 6.48 (dt, J¼ 6.2Hz, J¼ 1.8Hz, 1H), 5.91 (ddd, J¼ 6.1Hz, J¼ 2.4
Hz, J¼ 1.4Hz, 1H), 5.10–5.04 (m, 1H), 4.11 (dt, J¼ 6.2Hz, J¼ 3.3Hz, 2H),
3.25–3.05 (m, 16H), 1.86 (d, J¼ 1.3Hz, 3H), 1.73–1.49 (m, 16H), 1.22 (sext,
J¼ 7.4Hz, 16H), 0.91 (t, J¼ 7.3Hz, 24H); 13C-NMR (75MHz, D2O): d 166.8,
152.2, 138.1, 134.2, 125.1, 111.2, 89.8, 85.8 (d, J¼ 8.5Hz), 66.2 (d, J¼ 5.6Hz), 58.0,
23.0, 19.0, 12.8, 11.4; 31P-NMR (162MHz, D2O): d  8.32 (d, J¼ 21.7Hz),  11.23
(d, J¼ 21.7Hz); IR: 3,220, 1,645, 1,486 cm 1; MALDI-MS (ESIþ , m/z): [M-H]
calcd. for C10H14N2O10P2, 383.005; found, 382.928.
General procedure D: preparation of c-bis(4-alkanoyloxybenzyl)-d4TTPs 3.
D4TDP 6 (1.0 eq.) were once co-evaporated with DMF and then dissolved in
acetonitrile. Phosphoramidites 5 (1.7–2.0 eq.) were added and the solvent removed
in vacuum quantitatively. The residue was redissolved in a minimum of acetonitrile
or in a mixture of acetonitrile/THF (1:1), and the reaction was started by addition
of a 0.25-M solution of DCI in acetonitrile (1.2–1.4 eq.). After stirring for 1min the
reaction was cooled to  10 C, and a 5.5M solution of t-BuOOH in n-decane
(2.1–2.2 eq.) was added for oxidation. The mixture was stirred for 20min and the
volatile components were removed in vacuum. The reaction was monitored with
HPLC. If the conversion of d4TDP was not complete, the procedure was repeated
as described above. The crude products were purified by automatic RP-18 flash
chromatography followed by an ion exchange to the ammonium form with Dowex
50WX8 cation exchange resin and a second RP-18 chromatography (3a–g,l–q). For
elution water/acetonitrile (5–100%, 0–40min, flow 1mlmin 1) or water/THF
gradients (5–80%, 0–40min, flow 1mlmin 1 were used. Product-containing
fractions were pooled and the organic solvent evaporated. The remaining aqueous
solutions were freeze-dried and the desired product obtained as colourless solids.
c-Bis-(4-acetyloxybenzyl)-d4TTP 3a (ammonium salt). General procedure D
with 86mg d4TDP 6 (99 mmol, 1.0 eq.), 92mg 5a (0.20mmol, 2.0 eq.), 0.55ml
0.25M solution of DCI in acetonitrile (0.14mmol, 1.4 eq.), 40 ml 5.5M solution of
t-BuOOH in n-decane (0.22mmol, 2.2 eq.) in 0.7ml acetonitrile. The crude
product was purified using automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 46mg (58 mmol, 59%) colourless solid. UV (HPLC): lmax¼ 265
nm; HPLC: tR¼ 11.00min (method A); 8.75min (method B); 1H-NMR (400MHz,
CD3OD): d 7.67 (d, J¼ 1.3Hz, 1H), 7.46–7.40 (m, 4H), 7.13–7.06 (m, 4H), 6.94
(dt, J¼ 3.4Hz, J¼ 1.8Hz, 1H), 6.48 (dt, J¼ 5.9Hz, J¼ 1.9Hz, 1H), 5.82
(dt, J¼ 5.9Hz, J¼ 1.9Hz, 1H), 5.18 (d, J¼ 8.1Hz, 4H), 4.99–4.93 (m, 1H),
4.32–4.17 (m, 2H), 2.30 (s, 6H), 1.92 (d, J¼ 1.3Hz, 3H); 13C-NMR (101MHz,
CD3OD): d 171.1, 166.5, 152.8, 152.3, 138.7, 134.9, 134.9 (d, J¼ 6.8Hz), 130.4
(d, J¼ 2.7Hz), 127.3, 122.9, 112.0, 90.8, 87.1 (d, J¼ 8.8Hz), 70.3 (d, J¼ 6.1Hz),
67.6, 20.9, 12.5; 31P-NMR (162MHz, CD3OD): d  11.69 (d, J¼ 19.4Hz),  13.11
(d, J¼ 17.1Hz),  23.51 (t, J¼ 17.8Hz); IR: 3,191, 2,988, 1,756, 1,687, 1,193 cm 1;
MALDI-MS (m/z): [M-H] calcd. for C28H31N2O17P3, 759.076; found, 759.131.
c-Bis-(4-propanoyloxybenzyl)-d4TTP 3b (ammonium salt). General procedure
D with 87mg d4TDP 6 (0.10mmol, 1.0 eq.), 93mg 5b (0.20mmol, 2.0 eq.), 0.48ml
0.25M solution of DCI in acetonitrile (0.12mmol, 1.2 eq.), 38 ml 5.5M solution of
t-BuOOH in n-decane (0.21mmol, 2.1 eq.) in 0.5ml acetonitrile. The crude
product was purified using automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 35mg (43 mmol, 43%) colourless solid. UV (HPLC): lmax¼ 265
nm; HPLC: tR¼ 11.83min (method A); 10.09min (method B); 1H-NMR
(200MHz, CD3OD): d 7.63 (d, J¼ 1.3Hz, 1H), 7.44–7.32 (m, 4H), 7.09–6.99
(m, 4H), 6.90 (dt, J¼ 3.4Hz, J¼ 1.6Hz, 1H), 6.43 (dt, J¼ 5.9Hz, J¼ 1.7Hz, 1H),
5.77 (ddd, J¼ 5.9Hz, J¼ 2.4Hz, J¼ 1.4Hz, 1H), 5.12 (d, J¼ 8.0Hz, 4H), 4.94–4.89
(m, 1H), 4.31–4.08 (m, 2H), 2.58 (q, J¼ 7.5Hz, 4H), 1.86 (d, J¼ 1.3Hz, 3H), 1.20
(t, J¼ 7.5Hz, 6H); 13C-NMR (75MHz, CD3OD): d 174.5, 166.5, 152.8, 152.4,
138.7, 135.7, 134.9 (d, J¼ 7.6Hz), 130.4 (d, J¼ 2.4Hz), 127.2, 122.9, 112.0,
90.8, 87.2 (d, J¼ 9.0Hz), 70.3 (d, J¼ 5.6Hz), 67.6 (d, J¼ 6.3Hz), 28.3, 12.5, 9.3;
31P-NMR (81MHz, CD3OD): d  11.76 (d, J¼ 19.4Hz),  13.19 (d, J¼ 17.1Hz),
 23.51 (t, J¼ 18.4Hz); IR: 3,195, 2,987, 1,758, 1,691, 1,254 cm 1; MALDI-MS
(m/z): [M-H] calcd. for C30H35N2O17P3, 787.108; found, 787.275.
c-Bis-(4-pentanoyloxybenzyl)-d4TTP 3c (ammonium salt). General procedure
D with 90mg d4TDP 6 (0.10mmol, 1.0 eq.), 0.11 g 5c (0.21mmol, 2.0 eq.), 0.50ml
0.25M solution of DCI in acetonitrile (0.13mmol, 1.2 eq.), 40 ml 5.5M solution
of t-BuOOH in n-decane (0.21mmol, 2.1 eq.) in 0.5ml acetonitrile. The crude
product was purified using automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 43mg (49 mmol, 47%) colourless solid. UV (HPLC): lmax¼ 265
nm; HPLC: tR¼ 13.61min (method A); 1H-NMR (400MHz, CD3OD): d 7.59
(d, J¼ 1.5Hz, 1H), 7.38–7.32 (m, 4H), 7.04–6.97 (m, 4H), 6.87 (dt, J¼ 3.4Hz,
J¼ 1.7Hz, 1H), 6.39 (dt, J¼ 5.9Hz, J¼ 1.8Hz, 1H), 5.77 (ddd, J¼ 5.9Hz, J¼ 2.4
Hz, J¼ 1.4Hz, 1H), 5.12 (d, J¼ 8.1Hz, 4H), 4.94–4.84 (m, 1H), 4.26–4.08 (m, 2H),
2.57–2.50 (m, 4H), 1.84 (d, J¼ 1.5Hz, 3H), 1.71–1.61 (m, 4H), 1.47–1.26 (m, 4H),
0.93 (t, J¼ 7.4Hz, 6H); 13C-NMR (101MHz, CD3OD): d 173.8, 166.5, 152.7, 152.3,
138.6, 135.6, 134.8 (d, J¼ 7.3Hz), 130.5 (d, J¼ 3.1Hz), 127.2, 122.9, 112.0, 90.8,
87.1 (d, J¼ 8.8Hz), 70.4 (dd, J¼ 6.0Hz, J¼ 2.1Hz), 67.9 (d, J¼ 5.4Hz), 34.7, 28.1,
23.2, 14.1, 12.5; 31P-NMR (81MHz, CD3OD): d  11.76 (d, J¼ 19.3Hz),  13.19
(d, J¼ 17.1Hz),  23.51 (t, J¼ 18.2Hz); IR: 3,183, 2,959, 1,755, 1,687, 1,219 cm 1;
MALDI-MS (m/z): [M-H] calcd. for C34H43N2O17P3, 843.170; found, 843.267.
c-Bis-(4-heptanoyloxybenzyl)-d4TTP 3d (ammonium salt). General procedure
D with 99mg d4TDP 6 (0.11mmol, 1.0 eq.), 0.14 g 5d (0.23mmol, 2.0 eq.), 0.55ml
0.25M solution of DCI in acetonitrile (0.14mmol, 1.2 eq.), 44 ml 5.5M solution of
t-BuOOH in n-decane (0.24mmol, 2.1 eq.) in 0.5ml acetonitrile. The crude
product was purified using automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 41mg (44 mmol, 40%) colourless solid. UV (HPLC): lmax¼ 265
nm; HPLC: tR¼ 15.40min (method A); 1H-NMR (400MHz, CD3OD): d 7.68
(d, J¼ 1.2Hz, 1H), 7.46–7.39 (m, 4H), 7.11–7.05 (m, 4H), 6.95 (dt, J¼ 3.4Hz,
J¼ 1.6Hz, 1H), 6.48 (dt, J¼ 6.1Hz, J¼ 1.7Hz, 1H), 5.86–5.80 (m, 1H), 5.18
(d, J¼ 8.2Hz, 4H), 5.01–4.94 (m, 1H), 4.34–4.16 (m, 2H), 2.60 (t, J¼ 7.4Hz, 4H),
1.92 (d, J¼ 1.2Hz, 3H), 1.76 (quint, J¼ 7.4Hz, 4H), 1.51–1.34 (m, 12H), 0.96
(t, J¼ 6.8Hz, 6H); 13C-NMR (101MHz, CD3OD): d 173.8, 166.5, 152.8, 152.3,
138.4, 135.8, 134.9 (d, J¼ 7.8Hz), 130.5 (d, J¼ 2.9Hz), 127.2, 122.9, 112.1, 90.8,
87.2 (d, J¼ 8.9Hz), 70.4 (d, J¼ 6.8Hz), 67.9 (d, J¼ 4.9Hz), 35.0, 32.7, 29.9,
23.6, 25.9, 14.4, 12.5; 31P-NMR (162MHz, CD3OD): d  11.64 (br.s),  13.08
(d, J¼ 17.5Hz),  23.47 (br.s); IR: 3,190, 2,928, 1,756, 1,689, 1,250 cm 1;
MALDI-MS (m/z): [M-H] calcd. for C38H51N2O17P3, 899.233; found, 899.229.
c-Bis-(4-nonanoyloxybenzyl)-d4TTP 3e (ammonium salt). General procedure
D with 0.15 g d4TDP 6 (0.17mmol, 1.0 eq.), 0.22 g 5e (0.34mmol, 2.0 eq.), 0.88ml
0.25M solution of DCI in acetonitrile (0.22mmol, 1.3 eq.), 68 ml 5.5M solution of
t-BuOOH in n-decane (0.37mmol, 2.2 eq.) in 3ml acetonitrile. The crude product
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was purified using automatic RP-18 chromatography (water/acetonitrile gradient).
Yield: 70mg (71 mmol, 42%) beige solid. UV (HPLC): lmax¼ 265 nm; HPLC:
tR¼ 17.31min (method A); 1H-NMR (300MHz, CD3OD): d 7.65 (d, J¼ 1.3Hz,
1H), 7.42–7.35 (m, 4H), 7.07–7.00 (m, 4H), 6.92 (dt, J¼ 3.5Hz, J¼ 1.6Hz, 1H),
6.45 (dt, J¼ 6.1Hz, J¼ 1.7Hz, 1H), 5.79 (ddd, J¼ 6.0Hz, J¼ 2.4Hz, J¼ 1.7Hz,
1H), 5.14 (d, J¼ 8.1Hz, 4H), 4.96–4.90 (m, 1H), 4.31–4.13 (m, 2H), 2.57
(t, J¼ 7.4Hz, 4H), 1.88 (d, J¼ 1.3Hz, 3H), 1.72 (quint, J¼ 7.3Hz, 4H), 1.49–1.24
(m, 20H), 0.96–0.85 (m, 6H); 13C-NMR (75MHz, CD3OD): d 173.4, 166.5, 152.9,
152.3, 138.4, 135.8, 134.5, 130.2 (d, J¼ 2.4Hz), 126.9, 122.6, 111.9, 90.5, 86.8
(d, J¼ 9.5Hz), 70.1 (d, J¼ 5.2Hz), 67.6 (d, J¼ 5.6Hz), 34.7, 32.7, 30.1, 30.1, 29.9,
25.7, 23.5, 14.2, 12.2; 31P-NMR (162MHz, CD3OD): d  11.83 (d, J¼ 20.1Hz),
 3.28 (d, J¼ 17.5Hz),  23.82 (t, J¼ 18.8Hz); IR: 3,192, 3,062, 2,926, 1,757,
1,694, 1,250 cm 1; MALDI-MS (m/z): [M-H] calcd. for C42H59N2O17P3,
955.295; found, 955.296.
c-Bis-(4-decanoyloxybenzyl)-d4TTP 3f. General procedure D with 71mg
d4TDP 6 (82 mmol, 1.0 eq.), 0.11 g 5f (0.16mmol, 2.0 eq.), 0.40ml 0.25M solution
of DCI in acetonitrile (0.10mmol, 1.2 eq.), 32 ml 5.5M solution of t-BuOOH in
n-decane (0.18mmol, 2.2 eq.) in 1.2ml acetonitrile. The crude product was purified
using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 23mg
(21 mmol, 26%) colourless solid (counterions: 0.2 Bu4Nþ , 1.8 NH4þ ). UV
(HPLC): lmax¼ 265 nm; HPLC: tR¼ 18.06min (method A); 1H-NMR (400MHz,
CD3OD): d 7.69 (d, J¼ 1.4Hz, 1H), 7.46–7.39 (m, 4H), 7.12–7.05 (m, 4H), 6.96
(dt, J¼ 3.4Hz, J¼ 1.6Hz, 1H), 6.50 (dt, J¼ 6.0Hz, J¼ 1.7Hz, 1H), 5.86–5.81
(m, 1H), 5.19 (d, J¼ 8.1Hz, 4H), 5.00–4.95 (m, 1H), 4.35–4.17 (m, 2H), 3.30–3.23
(m, 1.5H), 2.61 (t, J¼ 7.4Hz, 4H), 1.93 (d, J¼ 1.4Hz, 3H), 1.76 (quint, J¼ 7.3Hz,
4H), 1.73–1.64 (m, 1.5H), 1.52–1.28 (m, 25.5H), 1.06 (t, J¼ 7.4Hz, 2.3H),
0.97–0.90 (m, 6H); 13C-NMR (101MHz, CD3OD): d 173.7, 166.7, 152.6, 152.6,
138.7, 135.8, 135.0 (d, J¼ 7.8Hz), 130.5 (d, J¼ 2.9Hz), 127.1, 122.9, 112.1, 90.9,
87.2 (d, J¼ 9.7Hz), 70.4 (dd, J¼ 5.6Hz, J¼ 1.7Hz), 67.9 (d, J¼ 4.8Hz), 59.5, 35.0,
33.0, 30.6, 30.4, 30.4, 30.2, 26.0, 23.7, 24.8, 19.4, 14.4, 13.9, 12.5; 31P-NMR
(162MHz, CD3OD): d  11.80 (d, J¼ 19.9Hz),  13.07 (d, J¼ 17.5Hz),  23.82
(br.s); IR: 3,174, 2,925, 1,758, 1,690, 1,249 cm 1; MALDI-MS (m/z): [M-H]
calcd. for C44H63N2O17P3, 983.327; found, 983.512.
c-Bis-(4-dodecanoyloxybenzyl)-d4TTP 3g. General procedure D with 74mg
d4TDP 6 (85 mmol, 1.0 eq.), 0.13 g 5g (0.17mmol, 2.0 eq.), 0.41ml 0.25M solution
of DCI in acetonitrile (0.11mmol, 1.2 eq.), 33 ml 5.5M solution of t-BuOOH in
n-decane (0.18mmol, 2.1 eq.) in 1.2ml acetonitrile and 1.0ml THF. The crude
product was purified by automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 44mg (37 mmol, 44%) colourless solid (counterions: 1.6
Bu4Nþ , 0.4 NH4þ ). UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 20.15min
(method A); 1H-NMR (400MHz, CD3OD): d 7.74 (d, J¼ 1.5Hz, 1H), 7.47–7.39
(m, 4H), 7.10–7.03 (m, 4H), 6.96 (dt, J¼ 3.4Hz, J¼ 1.6Hz, 1H), 6.56 (dt, J¼ 6.0
Hz, J¼ 1.8Hz, 1H), 5.83–5.78 (m, 1H), 5.22 (dd, J¼ 8.0Hz, J¼ 2.0Hz, 4H),
5.01–4.95 (m, 1H), 4.43–4.19 (m, 2H), 3.31–3.19 (m, 12.8H), 2.61 (t, J¼ 7.4Hz,
4H), 1.93 (d, J¼ 1.5Hz, 3H), 1.76 (quint, J¼ 6.7Hz, 4H), 1.73–1.63 (m, 12.8H),
1.44 (sext, J¼ 7.4Hz, 12.8H), 1.51–1.28 (m, 32H), 1.05 (t, J¼ 7.4Hz, 19.2H),
0.98–0.89 (m, 6H); 13C-NMR (101MHz, CD3OD): d 173.7, 166.5, 152.8, 152.2,
138.8, 136.2, 135.2 (d, J¼ 7.8Hz), 130.5 (d, J¼ 2.8Hz), 126.9, 122.8, 112.1, 90.8,
87.4 (d, J¼ 6.3Hz), 70.4 (d, J¼ 5.7Hz), 67.8, 59.4, 35.0, 33.1, 30.7, 30.7, 30.6, 30.4,
30.4, 30.2, 26.0, 23.7, 24.8, 20.7, 14.5, 14.0, 12.5; 31P-NMR (162MHz, CD3OD):
d  11.91 (br.s),  13.28 (d, J¼ 17.6Hz),  3.99 (br.s); IR: 3,203, 2,925, 1,757,
1,690, 1,262 cm 1; MALDI-MS (m/z): [M-H] calcd. for C48H69N2O17P3,
1039.389; found, 1039.561.
c-Bis-(4-tetradecanoyloxybenzyl)-d4TTP 3h. General procedure D with 48mg
d4TDP 6 (53mmol, 1.0 eq.), 85mg 5h (0.11mmol, 2.0 eq.), 0.28ml 0.25M solution
of DCI in acetonitrile (69 mmol, 1.3 eq.), 21 ml 5.5M solution of t-BuOOH in
n-decane (0.12mmol, 2.2 eq.) in 0.5ml acetonitrile and 0.7ml THF. The reaction
was restarted once. The crude product was purified using automatic RP-18
chromatography (water/THF gradient). Yield: 72mg (37 mmol, 70% (exclusive
contamination)) colourless solid (counterions: 1.0 Bu4Nþ , 1.0 DIPAHþ ),
contaminated with Bu4Nþ and diisopropylammonium salts. UV (HPLC):
lmax¼ 265 nm; HPLC: tR¼ 22.22min (method A); 1H-NMR (300MHz, THF-d8):
d 10.10 (s, 1H), 7.88 (d, J¼ 1.2Hz, 1H), 7.53–7.44 (m, 4H), 7.04–6.96 (m, 4H), 6.91
(dt, J¼ 3.3Hz, J¼ 1.6Hz, 1H), 6.62 (dt, J¼ 5.9Hz, J¼ 1.7Hz, 1H), 5.61–5.56 (m,
1H), 5.26–5.17 (m, 4H), 4.85–4.78 (m, 1H), 4.44–4.31 (m, 1H), 4.14–4.01 (m, 1H),
3.50–3.39 (m, 8H), 3.33–2.85 (m, 2H), 2.52 (t, J¼ 7.5Hz, 4H), 1.91 (d, J¼ 1.2Hz,
3H), 1.77–1.59 (m, 12H), 1.50–1.23 (m, 60H), 0.94 (t, J¼ 7.4Hz, 12H), 0.89
(t, J¼ 6.8Hz, 6H); 13C-NMR (75MHz, THF-d8): d 172.2, 164.9, 152.1, 151.8, 138.2,
136.9, 136.1 (d, J¼ 8.5Hz), 130.1 (d, J¼ 1.6Hz), 126.2, 122.3, 111.3, 90.1, 87.8
(d, J¼ 8.5Hz), 69.2 (d, J¼ 5.4Hz), 67.2, 59.3, 47.2, 34.9, 33.1, 30.8, 30.8, 30.8, 30.8,
30.7, 30.5, 30.5, 30.2, 26.0, 25.0, 23.8, 20.7, 19.9, 14.6, 14.4, 12.8; 31P-NMR
(162MHz, THF-d8): d  14.16 (d, J¼ 20.8Hz),  14.65 (d, J¼ 17.8Hz),  23.82
(t, J¼ 19.1Hz); IR: 3,400, 2,924, 1,757, 1,689, 1,263 cm 1; MALDI-MS (m/z):
[M-H] calcd. for C52H79N2O17P3, 1095.452; found, 1095.503.
c-Bis-(4-hexadecanoyloxybenzyl)-d4TTP 3i. General procedure D with 90mg
d4TDP 6 (0.10mmol, 1.0 eq.), 0.18 g 5i (0.21mmol, 2.0 eq.), 0.50ml 0.25M solu-
tion of DCI in acetonitrile (0.13mmol, 1.3 eq.), 42 ml 5.5M solution of t-BuOOH in
n-decane (0.23mmol, 2.2 eq.) in 0.3ml acetonitrile and 0.9ml THF. The reaction
was restarted once. The crude product was purified using automatic RP-18
chromatography (water/THF gradient). Yield: 96mg (64 mmol, 62%) colourless
solid (counterions: 1.0 Bu4Nþ , 1.0 DIPAHþ ). UV (HPLC): lmax¼ 265 nm;
HPLC: tR¼ 23.28min (method A); 1H-NMR (500MHz, THF-d8): d 10.22 (s, 1H),
7.88 (d, J¼ 1.3Hz, 1H), 7.48–7.42 (m, 4H), 7.05–6.99 (m, 4H), 6.92 (dt, J¼ 3.4Hz,
J¼ 1.6Hz, 1H), 6.55 (dt, J¼ 5.8Hz, J¼ 1.6Hz, 1H), 5.67–5.61 (m, 1H), 5.22–5.13
(m, 4H), 4.87–4.82 (m, 1H), 4.38–4.29 (m, 1H), 4.15–4.07 (m, 1H), 3.43–3.27
(m, 8H), 3.31–3.15 (m, 2H), 2.53 (t, J¼ 7.5Hz, 4H), 1.90 (d, J¼ 1.0Hz, 3H),
1.74–1.62 (m, 12H), 1.48–1.20 (m, 68H), 0.95 (t, J¼ 7.2Hz, 12H), 0.89 (t, J¼ 6.8
Hzm, 6H); 13C-NMR (75MHz, THF-d8): d 172.1, 164.9, 152.1, 152.0, 137.8, 136.3,
135.5 (d, J¼ 8.6Hz), 130.1, 126.6, 122.5, 111.3, 90.2, 87.3 (d, J¼ 7.7Hz), 69.4
(d, J¼ 7.2Hz), 67.0, 59.3, 47.4, 34.9, 33.0, 30.8, 30.8, 30.8, 30.8, 30.7, 30.5, 30.5,
30.2, 26.1, 24.8, 23.6, 20.7, 19.8, 14.6, 14.4, 12.8; 31P-NMR (202MHz, THF-d8):
d  12.56 (d, J¼ 19.6Hz),  13.38 (d, J¼ 17.5Hz),  24.17 (t, J¼ 18.5Hz);
IR: 2,987, 2,916, 1,756, 1,691, 1,251 cm 1; MALDI-MS (m/z): [M-H] calcd. for
C56H85N2O17P3, 1151.515; found, 1151.663.
c-Bis-(4-octadecanoyloxybenzyl)-d4TTP 3j. General procedure D with 87mg
d4TDP 6 (0.10mmol, 1.0 eq.), 0.19 g 5j (0.20mmol, 2.0 eq.), 0.52ml 0.25M
solution of DCI in acetonitrile (0.13mmol, 1.3 eq.), 38 ml 5.5M solution of t-
BuOOH in n-decane (0.21mmol, 2.1 eq.) in 0.3ml acetonitrile and 0.9ml THF.
The reaction was restarted once. The crude product was purified using automatic
RP-18 chromatography (water/THF gradient). Yield: 69mg (44 mmol, 44%)
colourless solid (counterions: 1.0 Bu4Nþ , 1.0 DIPAHþ ).
UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 19.45min (method C); 1H-NMR
(300MHz, THF-d8): d 10.16 (s, 1H), 7.84 (d, J¼ 1.4Hz, 1H), 7.50–7.41 (m, 4H),
7.05–6.96 (m, 4H), 6.91 (dt, J¼ 3.3Hz, J¼ 1.5Hz, 1H), 6.62–6.53 (m, 1H),
5.65–5.57 (m, 1H), 5.24–5.13 (m, 4H), 4.89–4.79 (m, 1H), 4.43–4.30 (m, 1H),
4.17–4.04 (m, 1H), 3.51–3.28 (m, 8H), 3.30–3.09 (m, 2H), 2.51 (t, J¼ 7.4Hz, 4H),
1.91 (d, J¼ 0.7Hz, 3H), 1.77–1.60 (m, 13H), 1.49–1.19 (m, 76H), 1.00–0.82
(m, 18H); 13C-NMR (75MHz, THF-d8): d 172.1, 164.8, 152.1, 151.9, 138.0, 136.6,
135.8 (d, J¼ 7.8Hz), 130.1, 126.5, 122.4, 111.3, 90.2, 87.5 (d, J¼ 8.4Hz), 69.2
(d, J¼ 5.3Hz), 67.1, 59.3, 47.2, 34.9, 33.1, 30.8, 30.8, 30.7, 30.5, 30.5, 30.3, 26.0,
24.9, 23.8, 20.8, 19.8, 14.6, 14.4, 12.8; 31P-NMR (162MHz, THF-d8): d  12.74
(d, J¼ 19.2Hz),  12.83 (d, J¼ 18.3Hz),  23.46 (t, J¼ 18.7Hz); IR: 2,959, 2,916,
1,756, 1,688, 1,252 cm 1; MALDI-MS (m/z): [M-H] calcd. for C60H95N2O17P3,
1207.577; found, 1207.670.
c-Bis(4-(Z)-octadec-9-enoyloxybenzyl)-d4TTP 3k. General procedure D with
96mg d4TDP 6 (0.11mmol, 1.0 eq.), 0.20 g 5k (0.22mmol, 2.0 eq.), 0.53ml 0.25M
solution of DCI in acetonitrile (0.13mmol, 1.2 eq.), 42 ml 5.5M solution of
t-BuOOH in n-decane (0.23mmol, 2.1 eq.) in 0.3ml acetonitrile and 0.9ml THF.
The reaction was restarted once. The crude product was purified using automatic
RP-18 chromatography (water/THF gradient). Yield: 99mg (64 mmol, 58%)
colourless solid (counterions: 1.0 Bu4Nþ , 1.0 DIPAHþ ). UV (HPLC):
lmax¼ 265 nm; HPLC: tR¼ 22.92min (method A); 1H-NMR (300MHz, THF-d8):
d 10.20 (s, 1H), 7.86 (s, 1H), 7.52–7.42 (m, 4H), 7.07–6.96 (m, 4H), 6.94–6.88 (m,
1H), 6.67–6.53 (m, 1H), 5.68–5.54 (m, 1H), 5.44–5.27 (m, 4H), 5.24–5.14 (m, 4H),
4.90–4.79 (m, 1H), 4.43–4.31 (m, 1H), 4.18–4.03 (m, 1H), 3.57–3.25 (m, 8H),
3.32–3.02 (m, 2H), 2.52 (t, J¼ 7.5Hz, 4H), 2.14–1.95 (m, 8H), 1.91 (s, 3H),
1.80–1.58 (m, 12H), 1.54–1.16 (m, 60H), 1.05–0.75 (m, 18H); 13C-NMR (75MHz,
THF-d8): d 172.1, 164.8, 152.1, 151.9, 138.0, 137.3, 135.9 (d, J¼ 7.9Hz), 130.7,
130.7, 130.1 (d, J¼ 1.5Hz), 126.3, 122.4, 111.2, 90.2, 87.6 (d, J¼ 8.8Hz), 69.1, 67.1,
59.3, 47.2, 34.9, 33.0, 30.9, 30.7, 30.5, 30.4, 30.3, 30.2, 28.2, 28.2, 25.9, 25.0, 23.7,
20.8, 19.8, 14.7, 14.4, 12.8; 31P-NMR (162MHz, THF-d8): d  14.44 (d, J¼ 19.0
Hz),  14.94 (d, J¼ 18.0Hz),  25.55 (t, J¼ 18.5Hz); IR: 3,358, 2,965, 2,924,
1,757, 1,689, 1,262 cm 1; MALDI-MS (m/z): [M-H] calcd. for C60H91N2O17P3,
1203.557; found, 1203.546.
c-Bis-(4-methyloxycarbonyloxybenzyl)-d4TTP 3l (ammonium salt). General
procedure D with 99mg d4TDP 6 (0.11mmol, 1.0 eq.), 0.11 g 5l (0.23mmol,
2.0 eq.), 0.59ml 0.25M solution of DCI in acetonitrile (0.15mmol, 1.3 eq.), 46 ml
5.5M solution of t-BuOOH in n-decane (0.25mmol, 2.2 eq.) in 0.7ml acetonitrile.
The crude product was purified using automatic RP-18 chromatography
(water/acetonitrile gradient). Yield: 49mg (59 mmol, 52%) colourless solid. UV
(HPLC): lmax¼ 265 nm; HPLC: tR¼ 11.28min (method A); 9.17min (method B);
1H-NMR (400MHz, CD3OD): d 7.68 (d, J¼ 1.2Hz, 1H), 7.43–7.38 (m, 4H),
7.16–7.11 (m, 4H), 6.92 (dt, J¼ 3.4Hz, J¼ 1.8Hz, 1H), 6.47 (dt, J¼ 6.0Hz,
J¼ 1.7Hz, 1H), 5.82 (ddd, J¼ 6.1Hz, J¼ 2.5Hz, J¼ 1.4Hz, 1H), 5.18 (d, J¼ 8.0
Hz, 4H), 4.96–4.90 (m, 1H), 4.31–4.15 (m, 2H), 3.86 (s, 6H), 1.88 (d, J¼ 1.2Hz,
3H); 13C-NMR (101MHz, CD3OD): d 166.7, 155.7, 152.8, 152.7, 138.7, 135.8, 135.4
(d, J¼ 7.6Hz), 130.5 (d, J¼ 3.5Hz), 127.1, 122.3, 112.1, 90.8, 87.3 (d, J¼ 9.5Hz),
70.3 (dd, J¼ 5.8Hz, J¼ 2.1Hz), 67.6 (d, J¼ 5.9Hz), 56.0, 12.5; 31P-NMR
(162MHz, CD3OD): d  11.79 (d, J¼ 19.8Hz),  13.23 (d, J¼ 17.6Hz),  23.71
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(t, J¼ 18.5Hz); IR: 3,191, 3,050, 1,764, 1,692, 1,263 cm 1; MALDI-MS (m/z):
[M-H] calcd. for C28H31N2O19P3, 791.066; found, 791.003.
c-Bis-(4-octyloxycarbonyloxybenzyl)-d4TTP 3m. General procedure D with
0.11 g d4TDP 6 (0.13mmol, 1.0 eq.), 0.18 g 5m (0.26mmol, 2.0 eq.), 0.68ml 0.25M
solution of DCI in acetonitrile (0.17mmol, 1.3 eq.), 53ml 5.5M solution of
t-BuOOH in n-decane (0.29mmol, 2.2 eq.) in 0.7ml acetonitrile. The crude
product was purified using automatic RP-18 chromatography (water/acetonitrile
gradient). Yield: 75mg (69mmol, 52%) colourless solid (counterions: 0.3 Bu4Nþ ,
1.7 NH4þ ). UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 16.72min (method A);
1H-NMR (400MHz, CD3OD): d 7.65 (d, J¼ 1.1Hz, 1H), 7.43MALDI-MS (m/z):
[M-H] calcd7.36 (m, 4H), 7.17MALDI-MS (m/z): [M-H] calcd7.09 (m, 4H),
6.91 (dt, J¼ 3.5Hz, J¼ 1.9Hz, 1H), 6.44 (dt, J¼ 6.0Hz, J¼ 1.8Hz, 1H), 5.82 (ddd,
J¼ 6.0Hz, J¼ 2.4Hz, J¼ 1.3Hz, 1H), 5.14 (d, J¼ 8.2Hz, 4H), 4.96–4.90 (m, 1H),
4.29–4.13 (m, 2H), 4.22 (t, J¼ 6.6Hz, 4H), 3.25–3.15 (m, 2.5H), 1.88 (d, J¼ 1.1Hz,
3H), 1.77–1.64 (m, 4H), 1.67–1.57 (m, 2.5H), 1.47–1.22 (m, 22.5H), 1.00 (t, J¼ 7.3
Hz, 3.8H), 0.90 (t, J¼ 6.7Hz, 6H); 13C-NMR (101MHz, CD3OD): d 166.5, 155.1,
152.7, 152.7, 138.6, 135.7, 135.2 (d, J¼ 7.6Hz), 130.5 (d, J¼ 2.3Hz), 127.2, 122.3,
112.0, 90.8, 87.3 (d, J¼ 9.5Hz), 70.3 (dd, J¼ 5.4Hz, J¼ 1.4Hz), 70.0, 67.8
(d, J¼ 5.6Hz), 59.4, 32.9, 30.3, 30.3, 29.7, 26.8, 24.7, 23.7, 20.7, 14.5, 14.0, 12.5;
31P-NMR (162MHz, CD3OD): d  11.68 (d, J¼ 19.3Hz),  13.15 (d, J¼ 16.1Hz),
 23.53 (t, J¼ 18.0Hz); IR: 3,198, 2,926, 1,760, 1,690, 1,250 cm 1; MALDI-MS
(m/z): [M-H] calcd. for C42H59N2O19P3, 987.285; found, 987.396.
c-Bis-(4-dodecyloxycarbonyloxybenzyl)-d4TTP 3n. General procedure D with
80mg d4TDP 6 (92 mmol, 1.0 eq.), 0.15 g 5n (0.19mmol, 2.0 eq.), 0.48ml 0.25M
solution of DCI in acetonitrile (0.12mmol, 1.3 eq.), 37 ml 5.5M solution of
t-BuOOH in n-decane (0.20mmol, 2.1 eq.) in 0.5ml acetonitrile and 0.5ml THF.
The crude product was purified using automatic RP-18 chromatography
(water/acetonitrile gradient). Yield: 52mg (38 mmol, 41%) colourless solid
(counterions: 1.1 Bu4Nþ , 0.9 NH4þ ). UV (HPLC): lmax¼ 265 nm; HPLC:
tR¼ 20.53min (method A); 1H-NMR (300MHz, CD3OD): d 7.70 (d, J¼ 1.3Hz,
1H), 7.43–7.36 (m, 4H), 7.19–7.11 (m, 4H), 6.94 (dt, J¼ 3.4Hz, J¼ 1.7Hz, 1H),
6.52 (dt, J¼ 6.0Hz, J¼ 1.8Hz, 1H), 5.80 (ddd, J¼ 6.0Hz, J¼ 2.4Hz, J¼ 1.4Hz,
1H), 5.19 (d, J¼ 8.0Hz, 4H), 5.00–4.93 (m, 1H), 4.37–4.15 (m, 2H), 4.25
(t, J¼ 6.6Hz, 4H), 3.29–3.14 (m, 9H), 1.92 (d, J¼ 1.3Hz, 3H), 1.80–1.66
(m, 4H), 1.71–1.58 (m, 9H), 1.50–1.25 (m, 45H), 1.03 (t, J¼ 7.4Hz, 13.5H), 0.92
(t, J¼ 6.6Hz, 6H); 13C-NMR (75MHz, CD3OD): d 166.5, 155.1, 152.7, 152.6,
138.7, 136.0, 135.4 (d, J¼ 7.8Hz), 130.5 (d, J¼ 2.4Hz), 127.0, 122.3, 112.1, 90.8,
87.3 (d, J¼ 9.2Hz), 70.2 (d, J¼ 5.6Hz), 70.0, 67.8 (d, J¼ 6.0Hz), 59.5, 33.1, 30.8,
30.7, 30.6, 30.5, 30.3, 29.7, 26.8, 24.8, 23.7, 20.7, 19.4, 14.5, 13.9, 12.5; 31P-NMR
(162MHz, CD3OD): d  12.07 (d, J¼ 21.7Hz),  13.38 (d, J¼ 18.1Hz),  24.20
(dd, J¼ 21.7Hz, J¼ 18.1Hz); IR: 2,923, 1,760, 1,689, 1,248 cm 1; MALDI-MS
(m/z): [M-H] calcd. for C50H75N2O19P3, 1099.410; found, 1099.083.
c-Bis-(4-(butyl-ethane-1,2-diylbis(methylcarbamate))-oxybenzyl)-d4TTP 3o
(ammonium salt). General procedure D with 75mg d4TDP 6 (87 mmol, 1.0 eq.),
0.12 g 5o (0.15mmol, 1.7 eq.), 0.45ml 0.25M solution of DCI in acetonitrile
(0.11mmol, 1.3 eq.), 32 ml 5.5M solution of t-BuOOH in n-decane (0.18mmol,
2.1 eq.) in 1.5ml acetonitrile. The crude product was purified using automatic
RP-18 chromatography (water/acetonitrile gradient). Yield: 68mg (60 mmol, 69%)
colourless solid. UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 12.88min (method A);
1H-NMR (400MHz, CD3OD): d 7.68 (d, J¼ 1.0Hz, 1H), 7.48–7.42 (m, 4H),
7.15–7.09 (m, 4H, rotamers), 6.96 (dt, J¼ 3.5Hz, J¼ 1.7Hz, 1H), 6.49
(dt, J¼ 6.1Hz, J¼ 1.7Hz, 1H), 5.86–5.82 (m, 1H), 5.22–5.16 (m, 4H), 5.00–4.96
(m, 1H), 4.34–4.19 (m, 2H), 4.17–4.05 (m, 4H), 3.71–3.53 (m, 8H, rotamers),
3.15–2.96 (m, 12H), 1.93 (d, J¼ 1.0Hz, 3H), 1.72–1.56 (m, 4H, rotamers),
1.50–1.34 (m, 4H, rotamers), 0.96, 0.90 (t, J¼ 7.4Hz, 6H, rotamers); 13C-NMR
(101MHz, CD3OD): d 166.5, 158.3, 156.4, 152.8, 152.7, 138.6, 135.7, 134.6, 130.4
(d, J¼ 2.7Hz), 127.2, 123.1þ 122.9 (rotamers), 112.0 (C-5), 90.8 (C-10), 87.2
(d, J¼ 9.1Hz), 70.4 (dd, J¼ 5.4Hz, J¼ 2.5Hz), 67.9 (d, J¼ 5.8Hz), 66.8þ 66.6
(rotamers), 48.1þ 47.8 (rotamers), 47.6þ 47.3 (rotamers), 35.5þ 35.0 (rotamers),
32.2þ 32.2 (rotamers), 20.2, 14.1þ 14.1 (rotamers), 12.5; 31P-NMR (162MHz,
CD3OD): d  11.72 (d, J¼ 19.5Hz),  13.16 (d, J¼ 17.8Hz),  23.55
(t, J¼ 18.1Hz); IR: 3,191, 1,959, 1,687, 1,204 cm 1; MALDI-MS (m/z): [M-H]
calcd. for C44H63N6O21P3, 1103.319; found, 1103.383.
c-Bis-(4-(octyl-ethane-1,2-diylbis(methylcarbamate))-oxybenzyl)-d4TTP 3p
(ammonium salt). General procedure D with 80mg d4TDP 6 (92 mmol, 1.0 eq.),
0.15 g 5p (0.16mmol, 1.7 eq.), 0.48ml 0.25M solution of DCI in acetonitrile
(0.12mmol, 1.3 eq.), 37 ml 5.5M solution of t-BuOOH in n-decane (0.20mmol,
2.2 eq.) in 0.8ml acetonitrile. The crude product was purified using automatic
RP-18 chromatography (water/acetonitrile gradient). Yield: 73mg (58 mmol, 63%)
colourless solid. UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 15.98min (method A);
1H-NMR (400MHz, CD3OD): d 7.69 (br.s, 1H), 7.47–7.42 (m, 4H), 7.15–7.08
(m, 4H, rotamers), 6.96 (dt, J¼ 3.5Hz, J¼ 1.6Hz, 1H), 6.49 (dt, J¼ 6.0Hz,
J¼ 1.7Hz, 1H), 5.83 (dt, J¼ 6.0Hz, J¼ 1.7Hz, 1H), 5.22–5.16 (m, 4H), 5.00–4.96
(m, 1H), 4.34–4.19 (m, 2H), 4.15–4.05 (m, 4H), 3.72–3.53 (m, 8H, rotamers),
3.18–2.96 (m, 12H), 1.93 (s, 3H, H-7), 1.74–1.59 (m, 4H, rotamers), 1.47–1.22
(m, 20H), 0.92 (t, J¼ 6.2Hz, 6H); 13C-NMR (101MHz, CD3OD): d 166.3, 158.4,
156.5, 152.8, 152.8, 138.6, 135.7, 134.6, 130.4 (d, J¼ 2.7Hz), 127.2, 123.2þ 123.0
(rotamers), 112.0, 90.8, 87.2 (d, J¼ 9.2Hz), 70.5–70.3 (m), 67.9 (d, J¼ 5.9Hz),
67.1þ 66.9 (rotamers), 48.2þ 47.9 (rotamers), 47.6þ 47.3 (rotamers), 35.5þ 35.4
(rotamers), 35.2þ 35.0 (rotamers), 32.9, 30.3, 30.3, 30.2þ 30.1 (rotamers), 27.0,
23.7, 14.5, 12.5; 31P-NMR (162MHz, CD3OD): d  11.71 (d, J¼ 19.2Hz),  13.16
(d, J¼ 16.7Hz),  3.54 (br.s, J¼ 17.2Hz); IR: 3,190, 2,925, 0,693, 1,205 cm 1;
MALDI-MS (m/z): [M-H] calcd. for C52H79N6O21P3, 1215.444; found, 1215.630.
c-Bis-(4-(dodecyl-ethane-1,2-diylbis(methylcarbamate))-oxybenzyl)-d4TTP
3q (ammonium salt). General procedure D with 78mg d4TDP 6 (90 mmol,
1.0 eq.), 0.22 g 5q (0.15mmol, 1.7 eq.), 0.47ml 0.25M solution of DCI in
acetonitrile (0.12mmol, 1.3 eq.), 36 ml 5.5M solution of t-BuOOH in n-decane
(0.20mmol, 2.2 eq.) in 3.0ml acetonitrile. The crude product was purified using
automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 36mg
(26 mmol, 29%) colourless solid. UV (HPLC): lmax¼ 265 nm; HPLC: tR¼ 19.04
min (method A); 1H-NMR (400MHz, CD3OD): d 7.66 (br.s, 1H), 7.46–7.39
(m, 4H), 7.13–7.06 (m, 4H, rotamers), 6.95–6.92 (m, 1H), 6.47 (dt, J¼ 6.1Hz,
J¼ 1.7Hz, 1H), 5.83–5.79 (m, 1H), 5.20–5.13 (m, 4H), 4.98–4.93 (m, 1H),
4.33–4.16 (m, 2H), 4.14–4.01 (m, 4H), 3.71–3.53 (m, 8H, rotamers), 3.17–2.93
(m, 12H), 1.91 (s, 3H), 1.72–1.55 (m, 4H, rotamers), 1.45–1.21 (m, 36H), 0.91
(t, J¼ 6.6Hz, 6H); 13C-NMR (101MHz, CD3OD): d 166.4, 158.3, 156.4, 152.8,
152.7, 138.6, 135.7, 134.7–134.4 (m), 130.4 (d, J¼ 2.5Hz), 127.2, 123.2þ 123.0
(rotamers), 112.5, 90.8, 87.2 (d, J¼ 9.2Hz), 70.4 (dd, J¼ 5.3Hz, J¼ 2.2Hz), 67.9
(d, J¼ 5.0Hz), 67.1þ 66.9 (rotamers), 48.2þ 47.9 (rotamers), 47.6þ 47.3
(rotamers), 35.5þ 35.4 (rotamers), 35.2þ 34.9 (rotamers), 33.1, 30.7, 30.7, 30.6,
30.5, 30.4, 30.3, 30.2þ 30.1 (rotamers), 27.0, 23.7, 14.5, 12.5; 31P-NMR (162MHz,
CD3OD): d  11.74 (br.s),  13.10 (d, J¼ 16.1Hz),  23.51 (br.s); IR: 3,191,
2,922, 1,697, 1,205 cm 1; MALDI-MS (m/z): [M-H] calcd. for C60H95N6O21P3,
1327.569; found, 1327.607.
General procedure E: preparation of 5-Nitro-cycloSal-(4-alkanoyloxybenzyl)-
monophosphates 17. Corresponding 4-alkanoyloxybenzyl alcohol 9 (1.0 eq.) and
2.2 eq. diisopropylethylamine were dissolved in acetonitrile or THF and cooled to
 20 C. After dropwise addition of 2.0 eq., 5-nitrosaligenylchlorophosphite 18,
dissolved in acetonitrile or THF, the reaction mixture was allowed to warm to rt.
The solution was kept at this temperature for 2 h. For oxidation, oxone (4.0 eq.)
dissolved in water was added. The mixture was stirred for 15min and immediately
extracted with ethyl acetate. The organic phase was dried over Na2SO4, filtered and
the solvent was removed by evaporation. The crude products were purified using
preparative TLC (chromatotron).
5-Nitro-cycloSal-(4-acetyloxybenzyl)-monophosphate 17a. General procedure
E with a solution of 0.11 g 4-(hydroxymethyl)phenylacetate 9a (0.67mmol, 1.0 eq.)
and 0.25ml diisopropylethylamine (0.19 g, 1.5mmol, 2.2 eq.) dissolved in 12ml
acetonitrile, 0.31 g 5-nitrosaligenylchlorophosphite 18 (1.3mmol, 2.0 eq.) dissolved
in 15ml acetonitrile. For oxidation 1.7 g oxone (2.7mmol, 4.0 eq.) were used. The
crude product was purified using preparative TLC (CH2Cl2/MeOH 19:1 v/vþ 0.1%
HOAc). Yield: 0.12 g (0.31mmol, 46%) yellowish oil. TLC (PE/EE 1:1 v/vþ 0.1%
HOAc): Rf¼ 0.45; 1H-NMR (300MHz, CDCl3): d 8.15–8.05 (m, 1H), 7.99–7.94
(m, 1H), 7.38–7.29 (m, 2H), 7.08–6.95 (m, 3H), 5.42–5.27 (m, 2H), 5.18
(d, J¼ 10.1Hz, 2H), 2.25 (s, 3H); 13C-NMR (75MHz, CDCl3): d 172.2, 154.3
(d, J¼ 6.8Hz), 151.2, 143.8, 132.2 (d, J¼ 5.6Hz), 129.6, 125.4, 122.0, 121.4, 121.4,
119.7 (d, J¼ 9.2Hz), 70.2 (d, J¼ 6.0Hz), 67.9 (d, J¼ 7.1Hz), 21.0; 31P-NMR
(162MHz, CDCl3): d  10.30; IR: 3,075, 1,753, 1,193 cm 1; HRMS (ESIþ , m/z):
[MþNa]þ calcd. for C16H14NO8P, 402.0349; found, 402.0306.
5-Nitro-cycloSal-(4-nonanoyloxybenzyl)-monophosphate 17e. General
procedure E with a solution of 0.39 g 4-(hydroxymethyl)phenylnonanoate 9e
(1.5mmol, 1.0 eq.) and 0.55ml diisopropylethylamine (0.42 g, 3.3mmol, 2.2 eq.)
dissolved in 10ml acetonitrile, 0.69 g 5-nitrosaligenylchlorophosphite 18
(3.0mmol, 2.0 eq.) dissolved in 20ml acetonitrile. For oxidation, 3.6 g oxone
(5.9mmol, 4.0 eq.) was used. The crude product was purified using preparative
TLC (CH2Cl2/MeOH 19:1 v/vþ 0.1% HOAc). Yield: 0.57 g (1.2mmol, 80%) beige
solid. TLC (PE/EE 1:1 v/vþ 0.1% HOAc): Rf¼ 0.66; 1H-NMR (300MHz, CDCl3):
d 8.19–8.11 (m, 1H), 8.02–7.95 (m, 1H), 7.42–7.32 (m, 2H), 7.12–6.98 (m, 3H),
5.45–5.29 (m, 2H), 5.22 (d, J¼ 10.3Hz, 2H), 2.54 (t, J¼ 7.5Hz, 2H), 1.74 (quint,
J¼ 7.5Hz, 2H), 1.46–1.17 (m, 10H), 0.87 (t, J¼ 6.8Hz, 3H); 13C-NMR (75MHz,
CDCl3): d 172.2, 154.6 (d, J¼ 6.9Hz), 151.5, 143.9, 132.2 (d, J¼ 5.7Hz), 129.8,
125.6 (d, J¼ 1.4Hz), 122.3, 121.6, 121.4, 119.9 (d, J¼ 9.1Hz), 70.4 (d, J¼ 5.6Hz),
67.9 (d, J¼ 6.8Hz), 34.4, 31.9, 29.3, 29.2, 29.2, 24.9, 22.7, 14.2; 31P-NMR (81MHz,
CDCl3): d  10.73; IR: 2,921, 2,852, 1,749 cm 1; HRMS (ESIþ , m/z): [MþNa]þ
calcd. for C23H28NO8P, 500.1445; found, 500.1469.
5-Nitro-cycloSal-(4-octadecanoyloxybenzyl)-monophosphate 17j. General
procedure E with a solution of 0.43 g 4-(hydroxymethyl)phenyloctadecanoate 9j
(1.1mmol, 1.0 eq.) and 0.38ml diisopropylethylamine (0.29 g, 2.2mmol, 2.0 eq.)
dissolved in 20ml THF, 0.69 g 5-nitrosaligenylchlorophosphite 18 (1.7mmol,
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1.5 eq.) dissolved in 15ml THF. For oxidation, 2.0 g oxone (3.3mmol, 3.0 eq.) was
used. The crude product was purified using preparative TLC (CH2Cl2/MeOH
30:1 v/vþ 0.1% HOAc). Yield: 0.58 g (0.96mmol, 87%) yellowish solid. TLC
(PE/EE 1:1 v/vþ 0.1% HOAc): Rf¼ 0.72; 1H-NMR (400MHz, CDCl3): d 8.19–8.14
(m, 1H), 8.00 (d, J¼ 2.7Hz, 1H), 7.41–7.35 (m, 2H), 7.10–7.02 (m, 3H), 5.43–5.29
(m, 2H), 5.23 (d, J¼ 10.4Hz, 2H), 2.55 (t, J¼ 7.5Hz, 2H), 1.74 (quint, J¼ 7.5Hz,
2H), 1.46–1.19 (m, 28H), 0.87 (t, J¼ 6.8Hz, 3H); 13C-NMR (75MHz, CDCl3):
d 172.2, 154.6, 151.6, 144.0, 132.2 (d, J¼ 5.5Hz), 129.9, 125.7, 122.2, 121.6, 121.3,
120.0 (d, J¼ 9.4Hz), 70.5 (d, J¼ 5.8Hz), 68.1 (d, J¼ 7.1Hz), 34.5, 32.0, 29.8, 29.8,
29.7, 29.6, 29.5, 29.4, 29.2, 25.0, 22.8, 14.2; 31P-NMR (162MHz, CDCl3): d  10.30;
IR: 2,955, 2,849, 1,746 cm 1; HRMS (ESIþ , m/z): [MþNa]þ calcd. for
C32H46NO8P, 626.2853; found, 626.2821.
General procedure F: preparation of c-mono(4-alkanoyloxybenzyl)-d4TTP 4.
d4TDP 6 (1.0 eq.) was co-evaporated with DMF and dried in vacuum for 2 h. Then,
2.0–2.5 eq. of the corresponding 5-nitro-cycloSal-(4-alkanoyloxybenzyl)-mono-
phosphate 17 was dissolved in a minimum of DMF followed by a dropwise
addition to the nucleotide 8 dissolved in DMF. The reaction was stirred at rt for
20 h, and the solvent was removed under reduced pressure. The residue was
dissolved in CH2Cl2/ammonium acetate (1M). The layers were separated and the
aqueous layer was freeze-dried. The crude product thus obtained was purified using
automatic RP-18 chromatography (water/acetonitrile gradient). Subsequently, the
cations were exchanged to ammonium ions using Dowex 50WX8 (ammonium
form) cation exchange resin followed by a second RP-18 chromatography.
c-Mono-(4-acetyloxybenzyl)-d4TTP 4a (ammonium salt). General procedure
F with 70mg d4TDP 6 (81 mmol, 1.0 eq.) in 1.0ml DMF and 77mg 5-nitro-
cycloSal-(4-acetyloxybenzyl)-monophosphate 17a (0.20mmol, 2.5 eq.) in 0.5ml
DMF. Yield: 16mg (24mmol, 30%) colourless solid. UV (HPLC): lmax¼ 265 nm;
HPLC: tR¼ 10.88min (method A), 5.23min (method B); 1H-NMR (400MHz,
CD3OD): d 7.69 (d, J¼ 1.2Hz, 1H), 7.52–7.48 (m, 2H), 7.10–7.04 (m, 2H), 6.95
(dt, J¼ 3.5Hz, J¼ 1.6Hz, 1H), 6.53 (dt, J¼ 6.0Hz, J¼ 1.7Hz, 1H), 5.85 (ddd,
J¼ 6.1Hz, J¼ 2.4Hz, J¼ 1.7Hz, 1H), 5.07 (d, J¼ 6.2Hz, 2H), 5.02–4.97 (m, 1H),
4.32–4.17 (m, 2H), 2.29 (s, 3H), 1.93 (d, J¼ 1.2Hz, 3H); 13C-NMR (101MHz,
CD3OD): d 171.3, 166.7, 153.0, 151.7, 138.7, 137.4 (d, J¼ 8.7Hz), 135.9, 129.7,
127.0, 122.5, 112.0, 90.9, 87.3 (d, J¼ 9.1Hz), 68.2 (d, J¼ 5.3Hz), 67.8 (d, J¼ 6.1
Hz), 20.9, 12.5; 31P-NMR (162MHz, CD3OD): d  10.95 (d, J¼ 19.0Hz),  11.27
(d, J¼ 18.8Hz),  22.04 (t, J¼ 18.8Hz); IR: 3,190, 2,988, 1,687, 1,663, 1,217 cm 1;
MALDI-MS (m/z): [M-H] calcd. for C19H23N2O15P3, 611.024; found, 611.044.
c-Mono-(4-nonanoyloxybenzyl)-d4TTP 4e (ammonium salt). General proce-
dure F with 57mg d4TDP 6 (66 mmol, 1.0 eq.) in 1.0ml DMF and 63mg 5-nitro-
cycloSal-(4-nonanoyloxybenzyl)-monophosphate 17e (0.13mmol, 2.0 eq.) in 0.5ml
DMF. Yield: 15mg (20mmol, 30%) colourless solid. UV (HPLC): lmax¼ 265 nm;
HPLC: tR¼ 13.03min (method A); 1H-NMR (400MHz, CD3OD): d 7.70
(d, J¼ 1.4Hz, 1H), 7.53–7.47 (m, 2H), 7.08–7.03 (m, 2H), 6.96 (dt, J¼ 3.4Hz,
J¼ 1.6Hz, 1H), 6.53 (dt, J¼ 5.9Hz, J¼ 1.7Hz, 1H), 5.88–5.82 (m, 1H), 5.08
(d, J¼ 6.1Hz, 2H), 5.02–4.97 (m, 1H), 4.34–4.17 (m, 2H), 2.60 (t, J¼ 7.4Hz, 2H),
1.94 (s, 3H), 1.76 (quint, J¼ 7.3Hz, 2H), 1.50–1.29 (m, 10H), 0.94 (t, J¼ 6.7Hz,
3H); 13C-NMR (101MHz, CD3OD): d 173.9, 166.5, 152.8, 151.7, 138.7, 137.4,
135.9, 129.7, 127.0, 122.5, 112.0, 90.9, 87.3 (d, J¼ 5.2Hz), 68.2 (d, J¼ 5.3Hz), 67.8
(d, J¼ 5.4Hz), 35.0, 33.0, 30.4, 30.2, 30.2, 26.0, 23.7, 14.4, 12.5; 31P-NMR
(162MHz, CD3OD): d  10.99 (d, J¼ 19.5Hz),  11.31 (d, J¼ 18.8Hz),  22.12
(t, J¼ 18.7Hz); IR: 3,258, 2,973, 1,691, 1,066 cm 1; MALDI-MS (m/z): [M-H]
calcd. for C26H37N2O15P3, 709.133; found, 709.238.
c-Mono-(4-octadecanoyloxybenzyl)-d4TTP 4j (ammonium salt). General
procedure F with 56mg d4TDP 6 (65 mmol, 1.0 eq.) in 1.0ml DMF and 98mg
5-nitro-cycloSal-(4-octa-decanoyloxybenzyl)-monophosphate 17j (0.16mmol,
2.5 eq.) in 0.5ml DMF. Yield: 15mg (17 mmol, 26%) colourless solid. UV (HPLC):
lmax¼ 265 nm; HPLC: tR¼ 14.79min (method A); 1H-NMR (400MHz, CD3OD):
d 7.70 (d, J¼ 1.3Hz, 1H), 7.55–7.47 (m, 2H), 7.10–7.02 (m, 2H), 6.96 (dt, J¼ 3.4
Hz, J¼ 1.6Hz, 1H), 6.53 (dt, J¼ 6.0Hz, J¼ 1.7Hz, 1H), 5.87–5.83 (m, 1H), 5.09
(d, J¼ 5.8Hz, 2H), 5.02–4.97 (m, 1H), 4.36–4.16 (m, 2H), 2.60 (t, J¼ 7.4Hz, 2H),
1.94 (d, J¼ 1.3Hz, 3H), 1.76 (quint, J¼ 7.3Hz, 2H), 1.52–1.27 (m, 28H), 0.93
(t, J¼ 6.6Hz, 3H); 13C-NMR (101MHz, CD3OD): d 174.0, 166.6, 152.8, 151.7,
138.7, 137.2 (d, J¼ 7.6Hz), 135.9, 129.8, 127.1, 122.5, 112.0, 90.9, 87.2 (d, J¼ 8.1
Hz), 68.3, 67.8, 35.0, 33.0, 30.8, 30.7, 30.6, 30.5, 30.4, 30.2, 26.0, 23.7, 14.4, 12.5;
31P-NMR (162MHz, CD3OD): d  11.14 (d, J¼ 18.2Hz),  11.44 (d, J¼ 19.9Hz),
 23.82 (t, J¼ 18.6Hz); IR: 3,209, 3,066, 2,925, 1,757, 1,704, 1,251 cm 1; MALDI-
MS (m/z): [M-H] calcd. for C35H55N2O15P3, 835.274; found, 835.398.
30-O-Acetylthymidine 20. The synthesis was carried out as described
previously53.
TLC (CH2Cl2/MeOH 9:1): Rf¼ 0.59; 1H-NMR (400MHz, DMSO-d6): d 11.32
(br.s, 1H), 7.73 (d, J¼ 1.4Hz, 1H), 6.17 (dd, J¼ 8.7Hz, J¼ 5.9Hz, 1H), 5.24–5.19
(m, 1H), 5.20 (t, J¼ 5.1Hz, 1H), 3.99–3.95 (m, 1H), 3.62 (dd, J¼ 5.3Hz, J¼ 3.5Hz,
2H), 2.33–2.15 (m, 2H), 2.06 (s, 3H), 1.78 (d, J¼ 1.4Hz, 3H); 13C-NMR (101MHz,
DMSO-d6): d 170.0, 163.7, 150.5, 135.8, 109.7, 84.6, 83.7, 74.7, 61.3, 36.5, 20.8, 12.3.
IR: 3,468, 3,181, 1,706, 1,659 cm 1; HRMS (m/z): [MþNa]þ calcd. for
C12H16N2O5, 307.0901; found, 307.0882.
Thymidine diphosphate 22 (TDP, tetra-n-butylammonium salt). To a sus-
pension of 1.4 g 30-O-acetylthymidine 20 (1.8mmol, 1.0 eq.) in 30ml acetonitrile,
1.3ml diisopropylethlyamine (0.98 g, 7.6mmol, 1.5 eq.) was added, followed by
1.4 g 5-chlorosaligenylchlorophosphite 8 (6.1mmol, 1.2 eq.). The reaction mixture
was stirred for 3 h and subsequently cooled to 0 C. By addition of 1.4ml of a 5.5-M
solution of tert-butylhydroperoxide in n-decane (7.6mmol, 1.5 eq.) the phosphite
was oxidized for 20min. The solvent was removed in vacuum. The residue was
redissolved in CH2Cl2 and washed with 1M ammonium acetate solution. The
organic phase was dried over Na2SO4, filtered and the solvent was removed under
reduced pressure. The product 21 (quantitative conversion) was used for further
steps without purification.
5-chloro-cycloSal-30-O-acetyl-thymidinemonophosphate 21 (0.51 g; 1.0mmol,
1.0 eq.) was reacted with 0.89 g mono-(tetra-n-butylammonium)-monophosphate
(2.6mmol, 2.5 eq.) in 10ml DMF. After being stirred for 20 h, the solvent was
removed in vacuum and the residue was redissolved in a mixture of methanol/
water/tetra-n-butylammoniumhydroxide solution (40%) in water (7:3:1 v/v/v).
The reaction mixture was stirred for 17 h for deacetylation, followed by removal of
the solvent in vacuum. After extraction with water/ethyl acetate, the separated
aqueous layer was freeze-dried. The crude product was purified using RP-18
chromatography (water/acetonitrile gradient: 8:1 to 4:1 v/v). Yield: 0.46 g
(0.52mmol, 59%, 2 Bu4Nþ ) colourless solid. TLC (isopropanol/NH3/water
4:1:2.5 v/v/v): Rf¼ 0.19; 1H-NMR (300MHz, D2O): d 7.76 (d, J¼ 1.4Hz, 1H), 6.32
(dd, J¼ 7.6Hz, J¼ 6.4Hz, 1H), 4.67–4.58 (m, 1H), 4.22–4.08 (m, 3H), 3.30–2.25
(m, 16H), 2.43–2.24 (m, 2H), 1.91 (d, J¼ 1.4Hz, 3H), 1.74–1.51 (m, 16H), 1.35
(sext, J¼ 7.4Hz, 16H), 0.93 (t, J¼ 7.3Hz, 24H); 13C-NMR (75MHz, D2O): d 166.3,
151.6, 137.3, 111.7, 85.5, 84.9, 71.0, 65.3, 58.1, 38.6, 23.1, 19.1, 12.8, 11.6; 31P-NMR
(162MHz, D2O): d  10.89 (d, J¼ 20.0Hz),  11.53 (d, J¼ 20.0Hz); IR: 3,165,
2,960, 2,875, 1,683 cm 1; HRMS (ESIþ , m/z): [MþH]þ calcd. for
C10H16N2O11P2, 401.016; found, 400.789.
c-Bis-(4-nonanoyloxybenzyl)-TTP 3r (ammonium salt). General procedure D
with 0.11 g TDP 22 (0.13mmol, 1.0 eq.), 0.17 g 5e (0.25mmol, 2.0 eq.), 0.66ml
0.25M DCI solution (0.17mmol, 1.3 eq.), 46 ml 5.5M solution of t-BuOOH in
n-decane (0.25mmol, 2.0 eq.) in 0.7ml acetonitrile. The crude product was purified
using automatic RP-18 chromatography (water/acetonitrile gradient). Yield: 95mg
(94 mmol, 74%) colourless solid. UV (HPLC): lmax¼ 266 nm; HPLC: tR¼ 16.56
min (method A); 1H-NMR (300MHz, CD3OD): d 7.83 (d, J¼ 1.3Hz, 1H),
7.42–7.33 (m, 4H), 7.03–6.96 (m, 4H), 6.28 (dd, J¼ 7.6Hz, J¼ 6.0Hz, 1H), 5.17
(d, J¼ 8.0Hz, 4H), 4.65–4.58 (m, 1H), 4.30 (ddd, J¼ 11.4Hz, J¼ 5.9Hz, J¼ 2.8Hz,
1H), 4.24–4.14 (m, 1H), 4.01–3.90 (m, 1H), 2.54 (t, J¼ 7.4Hz, 4H), 2.31–2.18
(m, 1H), 2.12 (ddd, J¼ 13.5Hz, J¼ 6.1Hz, J¼ 3.3Hz, 1H), 1.89 (d, J¼ 1.3Hz, 3H),
1.75–1.51 (m, 4H), 1.47–1.21 (m, 20H), 0.93 (t, J¼ 6.7Hz, 6H); 13C-NMR
(75MHz, CD3OD): d 173.7, 166.7, 152.4, 152.2, 138.3, 135.2 (d, J¼ 7.1Hz), 130.5,
122.8, 112.0, 87.6, 85.8, 72.2, 70.2 (d, J¼ 5.4Hz), 67.0, 40.5, 35.0, 33.0, 30.4,
30.3, 30.2, 26.0, 23.7, 14.5, 12.7; 31P-NMR (162MHz, CD3OD): d  13.62
(d, J¼ 22.0Hz),  15.17 (d, J¼ 17.8Hz),  23.67 (d, J¼ 20.0Hz); IR: 3,182,
2,924, 1,755, 1,688 cm 1; MALDI-MS (m/z): [M-H] calcd. for C42H61N2O18P3,
973.306; found, 973.491.
Chemical hydrolysis of TriPPPro-d4TTP compounds 3a–q and intermediates
4a,e,j. Stock solutions (50mM in DMSO-d6) of the appropriate compounds were
prepared. After dilution of 11 ml with 100 ml Millipore water and 189 ml DMSO-d6
to 1.9mM hydrolysis solutions the reaction was started by the addition of 300 ml
PBS (50mM, pH 7.3). The solution was incubated at 37 C in a thermomixer. An
initial aliquot (25 ml) was taken directly and analysed by analytical HPLC at
265–266 nm. Further aliquots were taken for monitoring the kinetic hydrolysis.
The exponential decay curves (pseudo-first order) based on absolute integral values
were calculated with commercially available software (OriginPro 9.0G) and yielded
the half-lives t1/2(1) and t1/2(2) of the prodrugs via one determination.
Enzymatic hydrolysis of TriPPPro-d4TTP compounds 3a–n and intermediates
4a,e,j with PLE. Overall, 20 ml of the appropriate 50mM DMSO-d6 stock solution
were diluted to 6.0mM by addition of 83.3 ml DMSO-d6 as well as 83.3 ml Millipore
water. Furthermore, 140 ml of the 6.0mM solution was diluted with 105ml DMSO-
d6 and 700 ml 50mM PBS buffer. The reaction was started by addition of 52.5 ml of
PLE in PBS buffer (3mgml 1) and the mixture was incubated at 37 C in a
thermomixer. At different times, aliquots (125 ml) were taken and treated as fol-
lows: (a) for 3a–g,l,m and 4a,e the reaction was stopped by addition to 132.5 ml
MeOH. The mixture was kept for 5min on ice followed by centrifugation for 5min
(13,000 r.p.m.). The supernatant was filtered (Chromafil RC-20/15 MS, 0.2 mm) and
stored in liquid nitrogen. (b) For 3h,i,k,n and 4j, the sample was directly frozen in
liquid nitrogen. The solution was defrosted followed by ultrasonication for 10min.
After centrifugation for 5min, the supernatant was filtered (Chromafil AO-20/3,
0.2 mm) and stored at  196 C. (c) For 3j, the mixture was diluted with 70 ml THF
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(HPLC grade) and frozen in liquid nitrogen followed by defrosting, ultrasonication,
centrifugation, filtration and stored as described for (b).
Samples were defrosted and 50–80 ml were subjected to HPLC analysis. The
calculation of t1/2 was performed analogously to that for the chemical hydrolysis
studies.
Enzyme-catalysed hydrolysis of TriPPPro-d4TTP compounds 3a–n and
intermediates 4a,e,j in CEM cell extracts. A volume of 10ml of the appropriate
50mM DMSO-d6 stock solution was diluted to 6.0mM hydrolysis solution by
addition of 73.3 ml DMSO-d6. Seven different samples including 10 ml water and
10ml hydrolysis solution were prepared. The reaction was started by addition of
50ml human CEM cell extract and the mixture was incubated at 37 C for different
time periods of hydrolysis. The work-up depended on the particular compound: (a)
for 3a–f,l,m,p and 4a,e the reactions were stopped by addition of 150 ml MeOH.
The solution was kept on ice for 5min followed by centrifugation for 5min
(13,000 r.p.m.). The supernatants were filtered (Chromafil RC-20/15 MS, 0.2 mm)
and stored in liquid nitrogen. (b) For 3g–i,k,n and 4j, the samples were directly
frozen in liquid nitrogen. The solution was defrosted followed by ultrasonication
for 10min. After centrifugation for 5min the supernatants were filtered (Chromafil
AO-20/3, 0.2 mm) and stored at  196 C. (c) For 3j the mixture was diluted with
70ml THF (HPLC grade) and frozen in liquid nitrogen followed by defrosting,
ultrasonication, centrifugation, filtration and stored as described for (b). Samples
were defrosted and 50–80 ml were subjected to HPLC analysis. The calculation of
t1/2 was performed analogously to that for the chemical hydrolysis studies.
Preparation of cell extracts. Human CD4þ T-lymphocyte CEM cells were grown
in RPMI-1640-based cell culture medium to a final density ofB3  106 cellsml 1.
Then, cells were centrifuged for 10min at 1,250 r.p.m. at 4 C, washed twice with
cold PBS and the pellet was resuspended at 108 cellsml 1 and sonicated (Hielscher
Ultrasound Techn., 100% amplitude, three  times for 10 s) to destroy cell integrity.
The resulting cell suspension was then centrifuged at 10,000 r.p.m. to remove cell
debris, and the supernatant divided into aliquots before being frozen at  80 C
and used.
Anti-HIV activity assay. Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced
cytopathicity in wild-type CEM/0 and TK-deficient CEM/TK cell cultures was
measured in microtitre 96-well plates containingB3 105 CEM cellsml 1 infected
with 100 CCID50 of HIV per millilitre and containing appropriate dilutions of the
test compounds. After 4 5 days of incubation at 37 C in a CO2-controlled
humidified atmosphere, CEM giant (syncytium) cell formation was examined
microscopically. The EC50 (50% effective concentration) was defined as the com-
pound concentration required to inhibit HIV-induced giant cell formation by 50%.
Primer extension reactions. The used polymerase HIV RT was obtained from
Roboklon. The primer and template were purchased from Life Technologies.
Primer sequence:
50-TTGGATAGGAGGAAGTCCTGGTTGC-30
Template sequence:
50-AGACAAACCTATCCTCCTTCAGGACCAACG-30
The primer extension assays were performed under the following conditions:
The primer was labelled using [g32P]-ATP according to standard techniques.
After 5-min incubation at 95 C in 20mM Tris-HCl (pH 7.6) and 50mM NaCl, the
hybridization/annealing of the primer to the template strand was achieved by a
cooling phase from 95 to 20 C over 3 h. The final assay solution (20 ml) consists of
2.5 mM dNTPs or hydrolysate, 1 reaction buffer (50mM Tris-HCl (pH 8.6),
10mM MgCl2 and 40mM KCl), 0.02 mM of hybridization and 0.2 units of the
enzyme, which was incubated at 37 C for 10min. The reaction was stopped by
heating up to 80 C for 3min. The assays were separated using a denaturating
PAGE (15%). The results were visualized by phosphorimaging.
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